

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2017/109059 A1

(43) International Publication Date
29 June 2017 (29.06.2017)

- (51) International Patent Classification:
C12Q 1/68 (2006.01)
- (21) International Application Number:
PCT/EP2016/082355
- (22) International Filing Date:
22 December 2016 (22.12.2016)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
15201839.6 22 December 2015 (22.12.2015) EP
16176033.5 23 June 2016 (23.06.2016) EP
- (71) Applicants: VIB VZW [BE/BE]; Rijvisschestraat 120, 9052 Gent (BE). KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D [BE/BE]; Waaistraat 6 - Bus 5105, 3000 Leuven (BE). UNIVERSITEIT GENT [BE/BE]; Sint-Pietersnieuwstraat 25, 9000 Gent (BE).
- (72) Inventors: RAES, Jeroen; De Villegasstraat 54, 2600 Berchem (BE). ELEWAUT, Dirk; Blauwesteenstraat 14, 9070 Heusden (BE). TITO-TADEO, Raul Yhossef; Oud-Strijdersstraat 12 b002, 3020 Herent (BE). JOOSSENS, Marie; Groot-Brittaniëlaan 39, 9000 Gent (BE).
- (74) Common Representative: VIB VZW; Rijvisschestraat 120, 9052 Gent (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))



WO 2017/109059 A1

(54) Title: MICROBIAL MARKER IN INFLAMMATORY ARTHRITIS DISEASES

(57) Abstract: The present invention relates to methods for detecting the presence or assessing the risk of development of inflammatory arthritis diseases, more particularly of joint and/or gut inflammation in patients with inflammatory arthritis diseases, even more particularly of joint and/or gut inflammation in patients with spondyloarthritis (SpA) based on gut microbial markers. Also encompassed are methods to assess disease activity in patients with an inflammatory arthritis disease using said markers.

MICROBIAL MARKER IN INFLAMMATORY ARTHRITIS DISEASES**FIELD OF THE INVENTION**

The present invention relates to methods for detecting the presence or assessing the risk of development of inflammatory arthritis diseases, more particularly of joint and/or gut inflammation in
5 patients with inflammatory arthritis diseases, even more particularly of joint and/or gut inflammation in patients with spondyloarthritis (SpA) based on gut microbial markers. Also encompassed are methods to assess disease activity in patients with an inflammatory arthritis disease using said markers.

BACKGROUND

Arthritis is a condition in which one or more joints are inflamed. This can result in stiffness, soreness,
10 and in many cases, swelling. Inflammatory and non-inflammatory arthritis are the two most common forms of the condition. Non-inflammatory arthritis (e.g. osteoarthritis) is most commonly found in the knees, hips, spine, and hands. Even though it's called non-inflammatory, non-inflammatory arthritis can still result in some inflammation of the joints. However, this inflammation mostly results from wear and tear. In particular, osteoarthritis results from the breakdown of cartilage. Cartilage is the slick tissue that
15 covers and cushions the ends of the bones in a joint. Injuring a joint, breakdown of cartilage (e.g. in osteoarthritis patients) or everyday activities can contribute to non-inflammatory arthritis later in life. Being overweight and putting extra strain on the joints can also cause this.

Inflammatory arthritis diseases on the other hand are a group of autoimmune or auto-inflammatory diseases. Both autoimmune and auto-inflammatory disorders result from the immune system attacking
20 the body's own tissues, leading to increased inflammation. Inflammatory arthritis diseases include rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, juvenile idiopathic arthritis and systemic lupus erythematosus (lupus) among others. Inflammatory arthritis is characterized by pain, swelling, warmth and tenderness in the joints as well as morning stiffness that lasts for more than an hour. Because most inflammatory forms of arthritis are systemic (meaning they affect the entire body), other symptoms
25 related to inflammation may occur in other parts of the body. Depending on the specific form of arthritis, these symptoms could include skin rashes, eye inflammation, hair loss, dry mouth and fever.

Spondyloarthritis (SpA), also known as spondyloarthropathy, is an inflammatory arthritis disease. SpA is a chronic inflammatory condition involving the axial skeleton and/or peripheral joints and is characterized by axial inflammation (sacroiliitis and spondylitis) and/or asymmetrical peripheral
30 arthritis/enthesitis. Like with other inflammatory arthritis diseases, patients with SpA are often faced

with extra-articular manifestations such as psoriasis, uveitis and inflammatory bowel disease (IBD). A reciprocal overlap exists between IBD and SpA: about 5-10% of SpA patients develop IBD. Conversely, up to 30% of IBD patients may develop SpA-like articular inflammation. Importantly, up to 50% of all SpA patients show intestinal inflammation on a microscopic level, without associated gastrointestinal symptoms. Two types of inflammation can be distinguished based on histomorphological characteristics: an acute type resembling infectious enterocolitis, and a chronic type, quite similar to early Crohn's disease (CD). Previous studies have demonstrated a clinical relationship between gut and joint inflammation in SpA, with remission of joint inflammation being associated with disappearance of gut inflammation and vice versa (Abraham & Medzhitov, 2011, *Gastroenterology*, 140:1729-1737).

5

10 The current hypothesis of IBD pathogenesis involves an inappropriate immune response to dysbalanced intestinal bacteria in a genetically susceptible host (Lees et al. 2011, *Gut*, 60:1739-1753). The reciprocity between bowel and joint inflammation and the overlap with IBD, suggests that intestinal microbiota might play a role in SpA pathogenesis as well. Dysbiosis with a decrease in intestinal microbial diversity has been consistently found in IBD patients (for example, Huttenhower et al. 2014, *Immunity*, 40: 843-15 854) and an altered intestinal microbiota composition has also been described in unaffected relatives of CD patients (Joossens et al. 2011, *Gut*, 60:631-637). A gut microbial profile distinct from unaffected controls was described for SpA patients (Costello et al. 2014, *Arthritis & Rheumatology*, Nov 21), yet the relation between gut microbial composition, gut histology and disease activity markers in SpA remains unknown.

20 The diagnosis of inflammatory arthritis diseases (e.g. spondyloarthritis) relies predominantly on clinical and radiological criteria which are often unreliable and misdiagnosis is common. Although there is a need for diagnostic markers for inflammatory arthritis diseases, in particular of markers allowing early diagnosis of said diseases, no specific marker has been established yet. Several potential diagnostic markers have been described. It has been described that HLA-B27 positive subjects are at higher risk than the general population of developing the disorder. However, 10% of healthy individuals are also HLA-B27 positive. Thus, false positive diagnosis may occur and the specificity of HLA-B27 for SpA is limited.

25

The treatment goals for inflammatory arthritis diseases are maintenance of physical function, control of disease activity and prevention of radiographic progression. Today, treatments consist primarily anti-inflammatory and long-lasting therapies which may not impact the underlying causes of the disease. Furthermore, effective preventative treatments for inflammatory arthritis diseases are virtually non-existent.

30

For spondyloarthritis, assessment of disease severity in patients was initially based on using single-item measures (e.g. pain, stiffness, erythrocyte sedimentation rate [ESR], C-reactive protein [CRP], patient/physician global assessment) and composite indices (e.g. Bath Ankylosing Spondylitis Disease Activity Index - BASDAI). However, both have limitations because they measure only part of disease activity, and are fully patient or physician oriented. The composite index Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new instrument to measure disease activity in early spondyloarthritis and to establish thresholds as targets of treatment in patients with spondyloarthritis. It reflects disease activity from both the patient and the physician perspective, which are known to be inherently different. It includes the following items: back pain, duration of morning stiffness, patient global assessment of disease activity, peripheral pain or swelling, and an acute phase reactant, preferably CRP, alternatively ESR.

There is a need for improved means and methods for the treatment and/or prevention of spondyloarthritis and other inflammatory arthritis diseases. A need also exists for improved means and methods to diagnose and assess severity of these diseases and identify individuals predisposed to developing them.

SUMMARY OF THE INVENTION

In the current application, methods are provided for detecting the presence or assessing the risk of development of inflammatory arthritis diseases, more particularly spondyloarthritis. This is based on the finding of a significant difference in intestinal microbial composition in SpA patients with and without microscopic gut inflammation was surprisingly found. A similar significant difference in intestinal microbial composition was found between inflamed and healthy samples. Moreover, we identified *Dialister* as a microbial marker of disease activity and as a potential important microbial species in inflammatory arthritis pathogenesis.

In particular, we noticed increased bacterial diversity in inflamed versus non-inflamed colonic and ileal biopsies of SpA patients. The same increased bacterial diversity was seen in inflamed biopsies of SpA patients and biopsies of healthy subjects. Overall bacterial community composition was also significantly different between inflamed and non-inflamed or healthy biopsies. This was unexpected, since the art suggested that intestinal inflammation, such as that observed in patients with IBD, is associated with lower microbial diversity. In addition, the present study is the first to identify a particular bacterial species and correlate its presence/abundance to disease activity in SpA: we found the genus *Dialister* as a microbial marker that correlates with ASDAS in both ileum and colon biopsies. Moreover, these results could be confirmed using non-invasive samples such as stool samples and oral samples.

This application provides methods to detect the presence or to assess the risk of development of an inflammatory arthritis disease in a patient. The methods comprise the steps of (i) determining a gut microbiome profile for said patient and comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles, wherein said one or more gut microbiome reference profiles
5 comprise at least one of a positive gut microbiome reference profile based on results from control subjects with said inflammatory arthritis disease and a negative gut microbiome reference profile based on results from control subjects without said inflammatory arthritis disease, (ii) if said gut microbiome profile for said patient statistically significantly matches said positive gut microbiome reference profile, then concluding that said patient has or is at risk of developing said inflammatory arthritis disease;
10 and/or (iii) if said gut microbiome profile for said patient statistically significantly matches said negative gut microbiome reference profile, then concluding that said patient does not have or is not at risk of developing said inflammatory arthritis disease. The invention also provides methods to detect the presence or to assess the risk of development of joint or gut inflammation in a patient with an inflammatory arthritis disease. The methods comprise the steps of (i) determining a gut microbiome
15 profile for said patient and comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles, wherein said one or more gut microbiome reference profiles comprise at least one of a positive gut microbiome reference profile based on results from control subjects with joint inflammation in case the method is provided to detect joint inflammation in patients with an inflammatory arthritis disease or from control subjects with gut inflammation in case the method is
20 provided to detect gut inflammation in patients with an inflammatory arthritis disease and a negative gut microbiome reference profile based on results from control subjects without joint inflammation in case the method is provided to detect joint inflammation in patients with an inflammatory arthritis disease or from control subjects without gut inflammation in case the method is provided to detect gut inflammation in patients with an inflammatory arthritis disease, (ii) if said gut microbiome profile for
25 said patient statistically significantly matches said positive gut microbiome reference profile for joint inflammation, then concluding that said patient has or is at risk of developing joint inflammation or if said gut microbiome profile for said patient statistically significantly matches said positive gut microbiome reference profile for gut inflammation, then concluding that said patient has or is at risk of developing gut inflammation; and/or (iii) if said gut microbiome profile for said patient statistically
30 significantly matches said negative gut microbiome reference profile for joint inflammation, then concluding that said patient does not have or is not at risk of developing joint inflammation or if said gut microbiome profile for said patient statistically significantly matches said negative gut microbiome reference profile for gut inflammation, then concluding that said patient does not have or is not at risk of developing gut inflammation.

In some embodiments, a statistically significant match has a P value of 0.05 or less. In some embodiments, the gut microbiome profile is determined in a biological sample selected from a mucosal biopsy sample, a stool sample, a sample of the lumen content, an oral sample, a blood sample, a serum sample or a urine sample. In other embodiments, the gut microbiome profile may include one or more
5 of bacterial taxa identified in said biological sample; bacterial metabolic products in said biological sample; and proteins in said biological sample. In yet other embodiments, the gut microbiome profile is based on an analysis of amplification products of DNA and/or RNA of the gut microbiota, e.g. based on an analysis of amplification products of genes coding for one or more of small subunit rRNA, etc. In some
10 embodiments, the gut microbiome profile of said patient includes an indication of the presence and/or abundance of at least one of *Dialister* spp. In other embodiments, when the gut microbiome profile of said patient indicates the presence of *Dialister* spp., then said concluding step results in a conclusion that said patient has or is at risk of developing inflammatory arthritis disease, or joint inflammation or gut
inflammation or more particular spondyloarthritis.

In more particular embodiments, methods are provided to detect the presence or to assess the risk of
15 development of an inflammatory arthritis disease in a patient. The methods comprise the steps of (i) determining the abundance of a *Dialister* spp. in a biological sample of said patient, (ii) if said abundance for said patient is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least
70%, at least 80%, at least 90%, at least 100% higher or at least 2-fold, at least 3-fold, at least 4-fold, at
20 least 5-fold higher or between 2-fold and 10-fold higher or between 3-fold and 7-fold higher than the abundance of said *Dialister* spp. in said biological sample of a control subject without said inflammatory arthritis disease, then said concluding step results in a conclusion that said patient has or is at risk of
developing said inflammatory arthritis disease. Also, methods are provided to detect the presence or to
assess the risk of development of joint or gut inflammation in a patient with inflammatory arthritis. The
methods comprise the steps of (i) determining the abundance of a *Dialister* spp. in a biological sample
25 of said patient, (ii) if said abundance for said patient is at least 10%, at least 20%, at least 30%, at least
40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100% higher or at least
2-fold, at least 3-fold, at least 4-fold, at least 5-fold higher or between 2-fold and 10-fold higher or
between 3-fold and 7-fold higher than the abundance of said *Dialister* spp. in said biological sample of a
control subject without joint or gut inflammation, then said concluding step results in a conclusion that
30 said inflammatory arthritis patient has or is at risk of developing joint or gut inflammation respectively.

The application also provides a treatment method for a patient with an inflammatory arthritis disease comprising the steps of (i) determining a gut microbiome profile for said patient and comparing said gut
microbiome profile of said patient to one or more gut microbiome reference profiles, and based on said

step of comparing, (ii) concluding whether or not said patient has or is at risk of developing said inflammatory arthritis disease; and if said patient has or is at risk of developing said inflammatory arthritis disease, then selecting an appropriate treatment, and treating the patient according to said selected treatment. In some embodiments, the method is applied at one or more successive time points.

5 In other embodiments, the treatment includes a biological therapy, such as TNF-alpha blockers, anti-IL17A monoclonal antibodies, amongst others. The invention also provides a treatment method for a patient with an inflammatory arthritis disease comprising the steps of (i) determining the abundance of a *Dialister* spp. in a biological sample of said patient and comparing said abundance of said patient to the abundance of said *Dialister* spp. of one or more reference subjects, and based on said step of
10 comparing, (ii) concluding that said patient has or is at risk of developing said inflammatory arthritis disease if the abundance of said patient is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100% higher or at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold higher or between 2-fold and 10-fold higher or between 3-fold and 7-fold higher than the abundance of said *Dialister* spp. of said reference subjects and if said patient has
15 or is at risk of developing said inflammatory arthritis disease, then selecting an appropriate treatment, and treating the patient according to said selected treatment. In some embodiments, the method is applied at one or more successive time points. In other embodiments, the treatment includes a biological therapy, such as TNF-alpha blockers, anti-IL17A monoclonal antibodies, amongst others.

The application also provides for a method of monitoring the efficacy of a treatment in a patient with an
20 inflammatory arthritis disease, comprising the steps of (i) determining a gut microbiome profile for said patient, wherein said gut microbiome profile preferably comprises an indication of the presence and/or relative abundance of at least *Dialister* spp., and comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles, wherein said one or more gut microbiome reference profiles comprise one or more of a positive gut microbiome reference profile based on results from
25 control subjects with said inflammatory arthritis disease and a negative gut microbiome reference profile based on results from control subjects without said inflammatory arthritis disease; and (ii) if said gut microbiome profile for said patient statistically significantly matches said positive gut microbiome reference profile, then concluding that said treatment is not efficacious; and/or if said gut microbiome profile for said patient deviates statistically significantly from said negative gut microbiome reference
30 profile, then concluding that said treatment is efficacious, wherein said analyzing and comparing steps are performed at one or more successive time points with samples collected from said patient at one or more successive time periods during said treatment. However, a treatment may be deemed efficacious even if the treated patient's gut microbiome profile does not match that of an asymptomatic control, so long as the profile indicates a change away from the profile of a control group with gut inflammation,

e.g. lowered amounts of non-beneficial bacteria (e.g. at least about 10% lower, or 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even 100% decrease in the presence of at least one unwanted bacterium, and/or a corresponding increase in at least one beneficial or desirable bacterium). In some embodiments, the method further comprises the step of repeating said steps of said method at multiple time intervals, e.g. said method is carried out prior to commencement of said treatment, during said treatment and/or after cessation of said treatment. In some embodiments, said treatment is an anti-inflammatory treatment. In another embodiment, said anti-inflammatory treatment includes but is not limited to a biological therapy such as TNF-alpha blockers and/or anti-IL17A monoclonal antibodies.

The application also provides methods of monitoring the efficacy of a treatment for an inflammatory arthritis disease in a patient, said method comprises the steps of (i) determining the abundance of a *Dialister* spp. in a biological sample of said patient at two or more successive time points with samples collected from said patient at two or more successive time periods during said treatment, (ii) if the abundance of said *Dialister* spp. for said patient at a later time point of said two or more successive time points is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100% lower than the abundance of said *Dialister* spp. at an earlier time point of said two or more successive time points, then concluding that said treatment is efficacious. In some embodiment, said inflammatory arthritis patients having a likelihood of developing joint and/or gut inflammation. In some embodiments, said treatment is an anti-inflammatory treatment. In another embodiment, said anti-inflammatory treatment includes but is not limited to a biological therapy such as TNF-alpha blockers and/or anti-IL17A monoclonal antibodies.

Also encompassed is a method of assessing the disease activity or a change in a disease activity in a patient suffering from or at risk of developing inflammatory arthritis comprising the steps of (i) determining a gut microbiome profile for said patient, wherein said gut microbiome profile preferably comprises an indication of the presence and/or relative abundance of at least *Dialister* spp., and comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles at different stages of disease activity, based on results from control subjects characterized by different inflammatory arthritis disease activities; and (ii) if said gut microbiome profile for said patient statistically significantly matches said one or more gut microbiome reference profile for different stages of disease activity, then a disease activity score or a change in disease activity score is obtained for inflammatory arthritis development.

In alternative but equivalent wordings, the present invention also relates to the use of a gut microbiome profile to assess the presence or the risk of development of gut inflammation in a patient with inflammatory arthritis, or to assess disease severity in a patient with inflammatory arthritis, or to monitor

the efficacy of a treatment in a patient with inflammatory arthritis, wherein said gut microbiome profile preferably comprises an indication of the presence and/or abundance of at least *Dialister* spp. In particular embodiment, said inflammatory arthritis disease is spondyloarthritis. In other particular embodiments, said at least *Dialister* spp. is one or more *Dialister* spp. listed in Table 4 of this application.

5 In other particular embodiments, said at least *Dialister* spp. comprise at least *D. invisus*, *D. propionifaciens*, *D. succinatiphilus*, *D. microaerophilus* or *D. pneumomintes*.

The present invention also envisages a kit for carrying out the methods and uses as described above.

Further embodiments will be found in the detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

10 **Figure 1. Alpha and beta diversity of the biopsies.** Microbial diversity comprises richness (observed species) and evenness (how relative abundance or biomass is distributed among species). While richness is a direct measurement of OTUs (a), the Shannon Diversity Index estimates evenness (b). Our analysis did not detect significant differences between richness and evenness of colonic and ileal biopsies. Orange diamonds are the mean in plots (a) and (b). Bray Curtis dissimilarity distances (BCD) of the colonic
15 and ileal biopsies shows the variation in the community composition (beta diversity). In (c), we show the BCD of all pair wise comparison between a given biopsy (ileum or colon) and the rest of the biopsies. Empty circles represent outlier on the box plots, for all the samples there are outliers at 0 (Bray-Curtis distance against the same sample). After performing Welch t-test with 1000 permutations to test if the mean of the BCD of ileum and colonic biopsies of the same individual is significant different, only one
20 comparison was significant (sample G.168 –in orange *).

Figure 2. Microbial diversity and inflammation in ileal (a) and colonic (b) biopsies. Inflamed biopsies present significant higher Shannon Diversity Index (evenness) compared to non-inflamed samples ($p=0.030$ for ileum and $p=0.025$ for colon). The Shannon Diversity Index in ileal biopsies also showed a correlation between the type of inflammation and diversity: higher in acute, followed by chronic
25 inflammation and lower levels of diversity in non-inflamed biopsies. Microbial richness of ileal and colonic biopsies, grouped within inflammation categories, revealed higher richness in chronic than in acute and non-inflamed biopsies.

Figure 3. Ileal bacterial community diversity and local inflammation. The Bray-Curtis dissimilarity distances PCoA plot of bacteria community composition does not show a clear separation or clustering
30 by inflammation status. However, after conducting PERMANOVA, a p-value of 0.016 indicates significant

differences among bacterial community composition that, through hierarchical clustering, are found to be between inflamed and non-inflamed samples.

Figure 4. Colonic bacterial community diversity and local inflammation. The Bray-Curtis dissimilarity distances PCoA plot of bacteria community composition does not show a clear separation or clustering by inflammation status. However, after conducting PERMANOVA, a p-value of 0.011 indicates significant differences among bacteria community composition between at least one of the inflammation status categories from the others.

Figure 5. Spearman's rank correlation of the abundance of the genus *Dialister* with disease activity. a. *Dialister* positively correlated with ASDAS values ($\rho = 0.59$, $p = 5.53E-04$, $q = 0.026$); b. Results divided by bowel histology: acute ($\rho = 0.70$, $p = 0.350$, $q = 1.0$), chronic ($\rho = 0.74$, $p = 0.035$, $q = 0.105$) and non-inflamed ($\rho = 0.19$, $p = 0.802$, $q = 1.0$). *Dialister* abundance is presented by square root (Sqrt) to facilitate visualization.

Figure 6. Spearman's rank correlation of the abundance of the genus *Dialister* with disease activity. a. *Dialister* positively correlates with ASDAS values ($\rho = 0.5$, $p = 0.004$, $q = 0.167$). b. Results divided by bowel histology: acute ($\rho = 0.5$, $p = 0.225$, $q = 0.675$), chronic ($\rho = 0.72$, $p = 0.018$, $q = 0.054$) and non-inflamed ($\rho = 0.21$, $p = 0.246$, $q = 0.63$).

Figure 7. High concordance in the abundance of genus *Dialister* in ileal and colonic biopsies. Spearman rank correlation of abundance of *Dialister* in ileal vs colonic biopsies. ($\rho = 0.85$ and $p = 4.063e-09$, $q = 7.45E-06$).

Figure 8. Microbial diversity and inflammation in ileal biopsies from SpA patients (Inflamed (Acute/Chronic) -Non_Inflamed) and healthy controls (Normal). Microbial richness grouped within inflammation subtypes, revealed higher richness in chronic than in acute and non-inflamed biopsies. The Shannon Diversity Index showed a correlation between the type of inflammation and diversity: higher in acute, followed by chronic inflammation and lower levels of diversity in non-inflamed and healthy.

Figure 9. *Dialister* abundance in ileal and colonic biopsies from SpA patients and healthy controls (Normal). T-test analysis reveals that abundance of *Dialister* is significantly higher in ileal and colonic biopsies from the inflamed versus non-inflamed and healthy control groups. All these comparisons remain significant after multiple test correction for a FDR < 0.10 . *Dialister* abundance is presented by square root (Sqrt) to facilitate visualization.

Figure 10. *Dialister* abundance in stool samples from SpA patients. *Dialister* is present in 34 out of 46 stool samples from SpA patients whereby OTU_44 is the main contributor.

Figure 11. Positive *Dialister* correlation from stool samples with ASDAS. The positive correlation value of 0.13 for all stool samples (upper panel) can be divided in 0.29 for patients with inflammation (lower left) and -0.04 for patients without inflammation (lower right).

Figure 12. *Dialister* abundance positively correlates with levels of intake of non-steroidal anti-inflammatory drugs (NSAID).

Figure 13. Correlation between *Dialister* abundance in the sub gingival plaque of patients with axial spondyloarthritis (AxSpA) or without AxSpA (control). A reanalysis of the data of Bisanz et al 2016 revealed that the AxSpA group exhibits a higher mean abundance of *Dialister* (y-axis) in oral samples.

10 DETAILED DESCRIPTION OF THE INVENTION

The present invention will be described with respect to particular embodiments and with reference to certain drawings but the invention is not limited thereto but only by the claims. Any reference signs in the claims shall not be construed as limiting the scope. The drawings described are only schematic and are non-limiting. In the drawings, the size of some of the elements may be exaggerated and not drawn on scale for illustrative purposes. Where the term "comprising" is used in the present description and claims, it does not exclude other elements or steps. Where an indefinite or definite article is used when referring to a singular noun e.g. "a" or "an", "the", this includes a plural of that noun unless something else is specifically stated. Furthermore, the terms first, second, third and the like in the description and in the claims, are used for distinguishing between similar elements and not necessarily for describing a sequential or chronological order. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operation in other sequences than described or illustrated herein.

Unless otherwise defined herein, scientific and technical terms and phrases used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclatures used in connection with, and techniques of molecular and cellular biology, structural biology, biophysics, pharmacology, genetics and protein and nucleic acid chemistry described herein are those well-known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. See, for example, Sambrook et al. Molecular Cloning: A Laboratory Manual, 3th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.

(2001); Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates (1992, and Supplements to 2002); Rupp, Biomolecular crystallography: principles, Practice and Applications to Structural Biology, 1st edition, Garland Science, Taylor & Francis Group, LLC, an informa Business, N.Y. (2009); Limbird, Cell Surface Receptors, 3d ed., Springer (2004); Flow Cytometry Protocols, 2nd ed. Humana Press (2004); Antibody engineering, 2nd ed. Springer (2010).

In this application a systems biology approach was used to identify novel correlations between inflammatory arthritis diseases and gut microflora. For example, the studies disclosed herein successfully demonstrated a link between the composition of the gut microbiome in SpA patients with and without gut inflammation. This has led to the development of methods of assessing the propensity (risk, likelihood, etc.) of inflammatory arthritis, of inflammatory arthritis patients to develop joint and/or gut inflammation, methods of developing an appropriate treatment, and methods of monitoring the progress of treatment. Furthermore, the studies disclosed herein identified *Dialister* as a microbial marker of disease activity and as a potential important microbial species in inflammatory arthritis pathogenesis. This has led to the development of methods of assessing disease activity or a change in disease activity patients suffering from or at risk of developing inflammatory arthritis.

As used herein, the term “inflammatory arthritis” or “inflammatory arthritis disease” refers to a group of auto-inflammatory or autoimmune diseases characterized by inflammation of the joints and often other tissues and that includes rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthropathy, spondyloarthritis, inflammatory bowel disease (IBD) related arthritis, juvenile idiopathic arthritis, crystal-induced arthropathies among others. It differs from non-inflammatory arthritis such as osteoarthritis in its origin. While inflammatory arthritis originates from an autoimmune and/or auto-inflammatory response during which the tissue that lines and cushions the joints is attacked by the immune system, non-inflammatory arthritis is a degenerative joint disease whereby the joint’s cartilages is broken down by wear and tear.

As used herein, “a patient with inflammatory arthritis” is equivalent to the wording “a patient with an inflammatory arthritis disease”, “a patient suffering from inflammatory arthritis”, “a patient suffering from an inflammatory arthritis disease” or to the wording “an inflammatory arthritis patient”.

As used herein, the term “spondyloarthritis (SpA)” refers to a group of closely related, but clinically heterogeneous, inflammatory arthritis diseases with common features, including inflammation of the spine, eyes, skin and gastrointestinal tract. This group is also sometimes referred to as spondylitis and spondyloarthropathies and includes ankylosing spondylitis, non-radiographic axial SpA, juvenile onset SpA, reactive arthritis (Reiter’s syndrome), psoriatic arthritis, enteropathic arthritis (arthritis associated

with inflammatory bowel disease or inflammatory bowel disease (IBD) related arthritis), undifferentiated spondyloarthritis, and juvenile idiopathic arthritis. Characteristics of these diseases include inflammatory arthritis of the spine, peripheral arthritis that differs from rheumatoid arthritis, extra articular manifestations of inflammatory bowel disease, arthritis and uveitis, seronegativity for
5 rheumatoid factor and some degree of heritability, including the presence of the gene HLA-B27.

As used herein, “a patient with spondyloarthritis” is equivalent to the wording “a patient suffering from spondyloarthritis” or to the wording “a SpA patient”. SpA is the abbreviation of spondyloarthritis.

As used herein, the term “gut” generally comprises the stomach, the colon, the small intestine, the large intestine, cecum and the rectum. In addition, regions of the gut may be subdivided, e.g. the right versus
10 the left side of the colon may have different microflora populations due to the time required for digesting material to move through the colon, and changes in its composition in time. Synonyms include bowel, the gastrointestinal tract, or possibly the digestive system, although the latter is generally also understood to comprise the mouth, esophagus, etc.

The wording “gut inflammation” is equivalent to the wording “microscopic gut inflammation” as used
15 herein and refers to an inflammatory response in the gut as defined above. The inflammation can affect the entire gastrointestinal tract, can be more limited to for example the small intestine or large intestine but can also be limited to specific components or structures such as the bowel walls.

The term “inflammation” refers to complex but to the skilled person well known biological response of body tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. However, inflammation
20 is not a synonym for infection. Infection describes the interaction between the action of microbial invasion and the reaction of the body's inflammatory response — the two components are considered together when discussing an infection, and the word is used to imply a microbial invasive cause for the observed inflammatory reaction. Inflammation on the other hand describes purely the body's immunovascular response, whatever the cause may be. Inflammation is a protective response involving
25 immune cells, blood vessels, and molecular mediators. The function of inflammation is to eliminate the initial cause of cell injury, clear out necrotic cells and tissues damaged from the original insult and the inflammatory process, and to initiate tissue repair. The classical signs of inflammation are heat, pain, redness, swelling, and loss of function. Inflammation is a generic response, and therefore it is considered as a mechanism of innate immunity, as compared to adaptive immunity, which is specific for each
30 pathogen. Inflammation can be classified as either acute or chronic. Acute inflammation is the initial response of the body to harmful stimuli and is achieved by the increased movement of plasma and leukocytes (especially granulocytes) from the blood into the injured tissues. A series of biochemical

events propagates and matures the inflammatory response, involving the local vascular system, the immune system, and various cells within the injured tissue. Prolonged inflammation, known as chronic inflammation, leads to a progressive shift in the type of cells present at the site of inflammation, such as mononuclear cells, and is characterized by simultaneous destruction and healing of the tissue from the
5 inflammatory process.

The term “joint inflammation” refers to the presence of inflammation or of an inflammatory response in the joints. It involves the body’s immune systems attacking the joints. The inflammation can involve the whole joint, including the bone and the cartilage, but can also be more specific to particular components such as the synovial membrane, the synovium, the joint capsule or the connecting muscles. It typically
10 results in warm, swollen, and painful joints.

As used herein, the term “joint” or “articulation” (or “articular surface”) is the connection made between bones in the body which link the skeletal system into a functional whole. They are constructed to allow for different degrees and types of movement. Non-limiting examples of joints are knee joints, elbow joints, joints of the shoulder, joints of the hand, wrist joints, axillary articulations, sternoclavicular joints,
15 vertebral articulations, temporomandibular joints, sacroiliac joints, hip joints, articulations of foot.

As used herein, the term “microflora” refers to the collective bacteria in an ecosystem of a host (e.g. an animal, such as a human) or in a single part of the host’s body, e.g. the gut. An equivalent term is “microbiota”.

As used herein, the term “microbiome” refers to the totality of bacteria, their genetic elements
20 (genomes) in a defined environment, e.g. within the gut of a host, the latter then being referred to as the “gut microbiome”.

As used herein, the term “patient” or “individual” or “subject” typically denotes humans, but may also encompass reference to non-human animals, preferably warm-blooded animals, more preferably mammals, such as, e.g. non-human primates, rodents, canines, felines, equines, ovines, porcines, and
25 the like. A “patient” for the purpose of this application, is in need of treatment for an inflammatory arthritis disease, particularly spondyloarthritis, for joint and/or gut inflammation, more particularly for joint and/or gut inflammation linked to inflammatory arthritis, even more particularly for joint and/or gut inflammation linked to spondyloarthritis.

Also, the term “gut microbiome profile” is equivalent in wording as “gut microbiome signature” and
30 these wordings are used interchangeably herein. A gut microbiome profile represent the presence,

absence or the abundance of one or more of bacterial taxa identified in a biological sample; bacterial metabolic products in said biological sample; and proteins in said biological sample. In the context of the present application, the said bacterial metabolic products and said proteins are derived from *Dialister* spp. and/or *Dialister* spp. are one of the said bacterial taxa identified in said biological sample. The gut microbiome profile can be determined based on an analysis of amplification products of DNA and/or RNA of the gut microbiota, e.g. based on an analysis of amplification products of genes coding for one or more of small subunit rRNA, etc. and/or based on an analysis of proteins and/or metabolic products present in the biological sample. Gut microbiome profiles may be "compared" by any of a variety of statistical analytic procedures.

10 "Operational taxonomic unit" ("OTU", plural OTUs)" refers to a terminal leaf in a phylogenetic tree and is defined by a specific genetic sequence and all sequences that share sequence identity to this sequence at the level of species. A "type" or a plurality of "types" of bacteria includes an OTU or a plurality of different OTUs, and also encompasses a strain, species, genus, family or order of bacteria. The specific genetic sequence may be the 16S rRNA sequence or a portion of the 16S rRNA sequence or it may be a functionally conserved housekeeping gene found broadly across the eubacterial kingdom. OTUs share at least 95%, 96%, 97%, 98%, or 99% sequence identity. OTUs are frequently defined by comparing sequences between organisms. Sequences with less than 95% sequence identity are not considered to form part of the same OTU.

The term "sequence identity" as used herein refers to the extent that sequences are identical on a nucleotide-by-nucleotide basis over a window of comparison. Thus, a "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e. the window size), and multiplying the result by 100 to yield the percentage of sequence identity. A gap, i.e. a position in an alignment where a residue is present in one sequence but not in the other is regarded as a position with non-identical residues. Determining the percentage of sequence identity can be done manually, or by making use of computer programs that are available in the art. Examples of useful algorithms are PILEUP (Higgins & Sharp, CABIOS 5:151 (1989), BLAST and BLAST 2.0 (Altschul et al. J. Mol. Biol. 215: 403 (1990)). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>).

In order to reconstruct the evolutionary relationships and sequence identity of one bacterial isolate to another, phylogenetic approaches are used standardly exploiting the 16S rRNA sequence or a portion of

the 16S rRNA sequence of the bacteria, although any other sequence or the entire genome of the microorganisms to be analyzed can also be used. In microbiology, "16S rRNA sequence" refers to the sequence derived by characterizing the nucleotides that comprise the 16S ribosomal RNA gene(s). The bacterial 16S rRNA is approximately 1500 nucleotides in length.

5 The term "abundance" as used herein refers to the "amount" or "quantity" of particular taxa of gut microbiota, e.g. a bacterial genus or species that is relevant for inflammatory arthritis or that is relevant for the risk to develop joint and/or gut inflammation in a patient with inflammatory arthritis. In some embodiments, *Dialister* spp. are one of the said bacterial taxa. In other embodiments, the OTUs which are relevant for this application and are defined by their 16S rRNA sequence are presented in Table 4.

10 According to current classification these OTUs relate to *Dialister invisus*, *D. propionifaciens*, *D. succinatiphilus*, *D. micraerophilus* and *D. pneumosintes*. Methods to measure the "abundance" of particular bacteria such as *Dialister* spp. are known to the skilled person. As example, without the purpose of limiting, the "abundance" of e.g. *Dialister* spp. can be based on analysis of amplification products of genes coding for one or more small subunit rRNA, etc. and/or based on analysis of proteins

15 and/or metabolic products present in the biological sample, wherein the said genes, said proteins and/or said metabolic products are specific for *Dialister* spp.

The term "biological therapy" as used herein refers to a therapy that involves the use of living organisms, substances derived from living organisms, natural substances, artificial substances or laboratory-produced versions of such substances to stimulate or restore the ability of the body's immune system to

20 fight infection and disease. Non-limiting examples are TNF-alpha blockers, anti-IL17A monoclonal antibodies, amongst others.

The term "disease activity score" as used herein refers to an assessment to measure disease activity of inflammatory arthritis and more particular of SpA, to determine whether the signs and symptoms have reduced or stopped, and if treatment needs to be adjusted. Progression or worsening of the disease will

25 lead to an increased disease activity score. Non-limiting examples of disease activity scores for SpA patients are mentioned in the Background section. Also for rheumatoid arthritis, disease activity scores have been developed. A person skilled in the art is familiar with those. For rheumatoid arthritis, accurate reflections of disease activity include but are not limited to the Clinical Disease Activity Index, Disease Activity Score with 28-joint counts (erythrocyte sedimentation rate or C-reactive protein), Patient

30 Activity Scale (PAS), PAS-II, Routine Assessment of Patient Index Data with 3 measures, and Simplified Disease Activity Index (Anderson et al. 2012 Rheumatoid arthritis disease activity measures: American

college of rheumatology recommendations for use in clinical practice; *Arthritis Care & Research* 64, 640-647 incorporated here as reference).

In one embodiment, the present application provides methods to detect the presence or to assess the risk of development of an inflammatory arthritis disease in a patient, or to detect the presence or to assess the risk of development of joint and/or gut inflammation in a patient with inflammatory arthritis correlated with the presence or absence of (and/or abundance of) particular taxa of gut microbiota, or in a particular component of or location in the gut. Such inflammatory arthritis patients may have a higher than average or higher than normal chance of developing joint and/or gut inflammation compared to patients who have different gut microbiota, or different (relative) amounts of gut microbiota. Early identification of such a propensity allows early intervention, e.g. by altering the identity and/or abundance of gut microbiota associated with, and possibly causing, the disease, so that development of the disease may be avoided, or delayed, or the associated symptoms may be lessened. In a particular embodiment, said inflammatory arthritis disease is spondyloarthritis.

The methods of the application may involve steps of identifying a patient, the health or medical condition of whom might benefit from the knowledge provided by the method. The patient may be asymptomatic at the time of the analysis, or the patient may be in the early, or even later, stages of the disease, and can benefit from the knowledge of the status of the gut microflora. In order to practice the methods of the application, generally a sample of gut microbiota is obtained from the patient by any method known to those of skill in the art, and the sample is tested for the presence or absence of, and/or for the relative abundance of, at least one taxon of bacteria. Generally, the taxa which are targeted for assessment are one or more taxa, the presence of which is known to be correlated with a particular disease or condition, or with particular symptoms associated or correlated with a disease/condition. In some embodiments, identification of a single or a few (e.g. about 10 or fewer, or about 100 or fewer) key microbes may be sufficient to link the presence of the microbes to the likely development of a disease. However, in other embodiments, a broad taxonomy determination is made, e.g. dozens, hundreds or thousands (or more) taxa may be targeted for assessment of their presence and/or absence and/or relative abundance.

Suitable biological samples for interrogation using the methods of the application include but are not limited to: samples of gut contents and/or mucosal biopsies obtained directly by an invasive technique e.g. by surgery, by rectal or intestinal sampling via colonoscopy-type procedures, or by other means. Preferably, samples are obtained by less invasive methods, e.g. stool samples, blood samples, serum samples, urine samples etc. In one embodiment, oral samples, such as oral rinses, oral swabs, sub gingival plaques etc. are collected e.g. to correlate the oral microbiome with the gut microbiome, or for

other purposes. It is clear that the methods of current application do not include the sampling as such. Biological samples suitable and needed to practice the methods of the application are available before the methods are performed or executed.

After a sample is obtained, the types and/or the quantity (e.g. occurrence or abundance) in the sample
5 of at least one bacteria of interest is determined according to any method known to those of skill in the art. In addition, a total amount of bacteria may be determined, and then for each constituent bacteria, a fractional percentage (e.g. relative amount, ratio, distribution, frequency, percentage, etc.) of the total is calculated. The result is typically correlated with at least one suitable control result, e.g. control results
10 of the same parameter(s) obtained from asymptomatic individuals (negative control), and/or individuals known to have a disease of interest (positive control), or from subjects who have had the disease of interest and are being or have been treated, either successfully or unsuccessfully, etc.

If a strong correlation between a condition of interest and only one or a few microbes has previously been established, it is possible that detection of their presence (or absence) alone will suffice to justify or suggest a conclusion that the individual being tested does or does not have a high risk of developing
15 the condition of interest. In this case, detection may be done in any of a number of ways that are known to those of ordinary skill in the art, including but not limited to culturing the organism or the few organisms, conducting various analyses which are indicative of the presence of the microbe(s) of interest (e.g. by microscopy, using staining techniques, enzyme assays, antibody assays, etc.), or by sequencing of genetic material (DNA or RNA), and others. However, generally it will be beneficial to obtain as much
20 information as possible (or at least more information) regarding the microflora present in the sample. Older techniques (e.g. cultivation) are generally impractical for such an undertaking. Thus, newer nucleic acid sequencing technology (NextGen technology) is usually used. While any category (or categories) of nucleic acid(s) may be detected (usually amplified using, e.g. PCR techniques), particularly useful amplification strategies include the use of primers (e.g. universal primers) which amplify ribosomal RNA
25 genes (rRNA). Such techniques and primers are well-known to those of skill in the art, e.g. see: Quince et al., "Accurate determination of microbial diversity from 454 pyrosequencing data", *Nature methods* 6.9 (2009): 639-641; Whiteley et al., "Microbial 16S rRNA Ion Tag and community metagenome sequencing using the Ion Torrent (PGM) Platform", *Journal of microbiological methods* 91.1 (2012): 80-88; Caporaso et al. 2012, "Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms", *ISME J.*; Kozich et al., "Development of a dual-index sequencing strategy and
30 curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform", *Applied and environmental microbiology* 79.17 (2013): 5112-5120; of which the complete contents are hereby incorporated by reference.

In some embodiments, what is determined is the abundance of microbial families within the microbiome. However, characterization may be carried to more detailed levels, e.g. to the level of genus and/or species, and/or to the level of strain or variation (e.g. variants) within a species, if desired (including the presence or absence of various genetic elements such as genes, the presence or absence of plasmids, etc.). Alternatively, higher taxonomic designations can be used such as Phyla, Class, or Order. The objective is to identify which bacteria are present in the sample from the individual and the relative abundance of those microbes, e.g. expressed as a percentage of the total number of microbes that are present, thereby establishing a microbiome profile or signature for the individual being tested, e.g. for the region of the gut that has been sampled, or for the type of sample that is analyzed.

Once an individual patient's gut microbiome profile with respect to the targeted microbes has been determined, it is compared to known reference profiles obtained previously from control experiments. Such control experiments typically obtain "negative control" data from normal (healthy) individuals, i.e. comparable individuals who do not have disease symptoms, and positive control data from comparable individuals who do have the disease in question or particular disease symptoms or did have at the time of the analysis. Based on a comparative analysis between the patient's gut microbiome profile and one or more reference or control microbiome profiles (and usually corroborated statistically by methods that are well-known to those of ordinary skill in the art) the likelihood or risk of the patient for developing the disease or condition of interest is determined and thus can be used as a predictive diagnostic. For example, a person with a profile that is not similar to or within the range of values seen in normal control signatures, but which is more similar to or within ranges determined for positive controls, may be deemed to be at high risk for developing the disease. This is generally the case, for example, if his/her level or amount of at least one correlatable taxum is associated with the disease state with a statistically significant (P value) of less than about 0.05 (after multiple testing correction). Alternatively, for patients who are already symptomatic, a previous diagnosis may be corroborated, and/or an explanation of symptoms may be provided.

In other embodiments of the invention, when many taxa are being considered, the overall pattern of microflora is assessed, i.e. not only are particular taxa identified, but the percentage of each constituent taxon is taken in account, in comparison to all taxa that are detected and, usually, or optionally, to each other. Those of skill in the art will recognize that many possible ways of expressing or compiling such data exist, all of which are encompassed by the present invention, for example, the relationships may be expressed numerically or graphically as ratios or percentages of all taxa detected, etc. Further, the data may be manipulated so that only selected subsets of the taxa are considered (e.g. key indicators

with strong positive correlations). Data may be expressed, e.g. as a percentage of the total number of microbes detected, or as a weight percentage, etc.

In one embodiment, a nonparametric multivariate test such as Metastats, Analysis of Similarity, Principle Component Analysis, Non-Parametric MANOVA (Kruskal-Wallis), or other tests as described in a non-limitative way in the Example section, can be used to associate microbiome dysbiosis with a statistically significant (P value) of less than 0.05 (after multiple testing correction). Such tests are known in the art and are described, for example, by White et al., "Statistical methods for detecting differentially abundant features in clinical metagenomic samples", *PLoS Comput Biol* 5.4 (2009): e1000352; Segata et al., "Metagenomic biomarker discovery and explanation", *Genome Biol* 12.6 (2011): R60.

In other embodiments, phylogenetic methods such as Unifrac can be used to associate microbiome dysbiosis with the disease state with a statistically significant (P value) of less than 0.05 (after multiple testing correction). See, for example, Lozupone C, Knight R (2005) UniFrac: a new phylogenetic method for comparing microbial communities. *Appl Environ Microbiol* 71:8228-8235.

In other embodiments, still other methods can be used to associate microbiome dysbiosis with the disease state with a statistically significant (P value) of less than 0.05 (after multiple testing correction). See for example: Linear models (MaAsLin – Tickle T, Waldron L, Yiren Lu, Huttenhower C. Multivariate association of microbial communities with rich metadata in high-dimensional studies, e.g. as in Morgan et al. *Genome Biol* 2015, 16:67); Machine Learning tools such as Random Forests, Support Vector Machines; ecological visualization tools (vegan: Community Ecology Package. R Package [Internet]. 2015 J Oksanen, F Blanchet, R Kindt, P Legendre, P Minchin, R O'Hara), amongst others.

Once a patient is identified as having, or at high risk for developing, the disease or condition as described herein, suitable clinical intervention can be undertaken to alter the identity and/or the relative abundance of gut microflora in the individual. Accordingly, the present invention also encompasses the identification of suitable therapeutic targets for intervention and the selection/development of suitable treatment protocols. Exemplary treatments include but are not limited to: eliminating or lessening microflora associated with the condition e.g. using antibiotics or other therapies, for example, therapies that are specific for eliminating or lessening the number of targeted microflora, without affecting or minimally affecting desirable microflora, if possible; or increasing microflora that compete with the unwanted microflora, and/or which are correlated with a lack of disease symptoms, e.g. by administering probiotic and/or prebiotic supplements; by microfloral transplants (e.g. from healthy donors); by dietary modifications; by lifestyle modifications; etc.

In one aspect, the current application provides a method to detect the presence or to assess the risk of development of an inflammatory arthritis disease in a patient, comprising the steps of:

- determining a gut microbiome profile for said patient, said gut microbiome profile comprising an indication of the presence and/or abundance of at least *Dialister* spp. and comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles, wherein said one or more gut microbiome reference profiles comprise at least one of a positive gut microbiome reference profile based on results from control subjects with said inflammatory arthritis diseases and a negative gut microbiome reference profile based on results from control subjects without said inflammatory arthritis disease,
- if said gut microbiome profile for said patient statistically significantly matches said positive gut microbiome reference profile, then concluding that said patient has or is at risk of developing said inflammatory arthritis disease; and/or
- if said gut microbiome profile for said patient statistically significantly matches said negative gut microbiome reference profile, then concluding that said patient does not have or is not at risk of developing said inflammatory arthritis disease.

In one embodiment, a method is provided to detect the presence or to assess the risk of development of joint inflammation in a patient with an inflammatory arthritis disease, comprising the steps of:

- determining a gut microbiome profile for said patient, said gut microbiome profile comprising an indication of the presence and/or abundance of at least *Dialister* spp. and comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles, wherein said one or more gut microbiome reference profiles comprise at least one of a positive gut microbiome reference profile based on results from control subjects with joint inflammation and a negative gut microbiome reference profile based on results from control subjects without joint inflammation,
- if said gut microbiome profile for said patient statistically significantly matches said positive gut microbiome reference profile, then concluding that said patient has or is at risk of developing joint inflammation; and/or
- if said gut microbiome profile for said patient statistically significantly matches said negative gut microbiome reference profile, then concluding that said patient does not have or is not at risk of developing joint inflammation.

In another embodiment, the present application provides a method to detect the presence or to assess the risk of development of gut inflammation in a patient with inflammatory arthritis, comprising the steps of:

- determining a gut microbiome profile for said patient and comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles, wherein said one or more gut microbiome reference profiles comprise at least one of a positive gut microbiome reference profile based on results from control subjects with gut inflammation and a negative gut microbiome reference profile based on results from control subjects without gut inflammation,
- 5 – if said gut microbiome profile for said patient statistically significantly matches said positive gut microbiome reference profile, then concluding that said patient has or is at risk of developing gut inflammation; and/or
- 10 – if said gut microbiome profile for said patient statistically significantly matches said negative gut microbiome reference profile, then concluding that said patient does not have or is not at risk of developing gut inflammation

This is equivalent as saying that methods are provided for determining the presence or the risk of development of gut inflammation in a patient with inflammatory arthritis, comprising the steps of:

- determining a gut microbiome profile for said patient, wherein said gut microbiome profile comprising an indication of the presence and/or relative abundance of at least *Dialister spp.*;
- 15 – comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles, wherein said one or more gut microbiome reference profiles comprise at least one of a positive gut microbiome reference profile based on results from control subjects with gut inflammation and a negative gut microbiome reference profile based on results from control
- 20 subjects without gut inflammation;

wherein a gut microbiome profile for said patient that statistically significantly matches said positive gut microbiome reference profile is indicative for said patient to have or to be at risk of developing gut inflammation.

The studies described herein have demonstrated that the presence and/or absence and/or abundance of certain genera of bacteria are associated with inflammatory arthritis patients, and more particularly with joint and/or gut inflammation in inflammatory arthritis patients, and more particularly with joint and/or gut inflammation in SpA patients. In exemplary embodiments, in mucosal and stool samples, bacteria such as *Dialister* are associated with disease activity in SpA patients. Thus, in a preferred embodiment, the gut microbiome profile of the inflammatory arthritis patient preferably comprises an indication of the presence and/or abundance of at least *Dialister spp.*, including but limited to, *Dialister succinatiphilus*, *Dialister invisus*, amongst others. In another preferred embodiment, said at least *Dialister spp.* comprises one or more *Dialister spp.* that comprise a 16S rRNA sequence with an at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 100% identity to a 16S

rRNA sequence selected from Table 4. In another preferred embodiment, said at least *Dialister* spp. comprises one or more *Dialister succinatiphilus*, *Dialister invisus*, *Dialister propionifaciens*, *Dialister micraerophilus* or *Dialister pneumosintes* or combinations thereof. In another preferred embodiment, said at least *Dialister* spp. comprises one or more *Dialister* OTUs as listed in Table 4. In another preferred
5 embodiment, said at least *Dialister* spp. comprises at least OTU44, OTU60 or OTU62 as specified in Table 4.

Further embodiments of the invention provide methods for determining reference gut microbiome profiles, and databases comprising the same. Such profiles constitute prototypes or models for use as references when the assessment of an individual's microflora is undertaken. In some embodiments,
10 control signatures are collected and averaged or amalgamated to develop reference profiles which are correlated with a disease or condition of interest (and/or with the absence of the disease/condition). The reference profiles may be in the form of e.g. sequences which are characteristic of particular bacterial types, according to any useful classification (phylum, order, class, genus, species, strain, type, etc.). Further, the reference profiles generally include this information for relevant groups and subgroups
15 of microflora, e.g. those associated with a particular disease, condition, etc. The characteristics of the reference profiles are generally recorded (stored, compiled, etc.) in an electronic computerized catalog, library, database, etc. that is accessible to a practitioner of the invention. Such databases may include Genbank, the Ribosomal Database, Greengenes, Silva, amongst others. The invention also encompasses computer programs (e.g. executable software programs, and/or computers configured to carry out the
20 programs), which enable a practitioner to enter analytical data into the system (e.g. the results of rRNA PCR amplification of a stool sample, which may be the patient's gut microbiome profile) and to carry out a comparison to the stored reference profiles. Output from the program may include an expression of the level of similarity between the patient's signature and one or more relevant stored reference profiles, and/or the statistical likelihood that the patient already has or is likely to develop a disease or
25 condition associated with one or more reference profiles.

In some embodiments, the gut microbiome profile of a subject includes (or is) the result(s) of an analysis of the metabolome of the subject. In other words, instead of, or in addition to, determining the identity, the presence or absence, and/or abundance of bacteria in the gut, the identity, presence or absence and/or abundance of selected bacterial metabolic products of interest is determined. Exemplary
30 metabolites include but are not limited to indoles, short chain fatty acids, amino acids, bile acids, etc. The metabolites may be associated with (e.g. characteristic of) one or more bacterial taxa of interest. Exemplary metabolites that may be included in such a gut metabolome signature include but are not limited to volatile organic compounds detected by GC-MS, and hydrophobic and hydrophilic organic

compounds detected by LC-MS. In some embodiments, nuclear magnetic resonance (NMR) is utilized for detection. Other detectable metabolites are known to those of skill in the art.

In yet other embodiments of the application, the gut microbiome profile of a subject may be, or may include, results obtained by analyzing the protein content of a biological sample (e.g. a gut sample), of a
5 subject. The results may include the identity of the proteins, the presence or absence of selected proteins, the abundance of the proteins (e.g. compared to suitable controls), etc. The proteins may be associated with (e.g. characteristic of) one or more bacterial taxa of interest. Exemplary proteins that may be included in such a gut proteome profile include but are not limited to those which are known to those of skill in the art.

10 In an alternative embodiment, a method is provided to detect the presence or to assess the risk of development of an inflammatory arthritis disease in a patient, comprising the steps of:

- determining the abundance of a *Dialister* spp. in a biological sample of said patients;
- if said abundance for said patient is at least 10%, at least 20%, at least 30%, at least 40%, at least
15 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100% higher or at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold higher or between 2-fold and 10-fold higher or between 3-fold and 7-fold higher than the abundance of said *Dialister* spp. in said biological sample of a control subject without said inflammatory arthritis disease, then concluding that said patient has or is at risk of developing said inflammatory arthritis disease.

This is equivalent as saying that a method is provided to detect the presence or to assess the risk of
20 development of an inflammatory arthritis disease in a patient, comprising the steps of:

- determining the abundance of a *Dialister* spp. in a biological sample of said patients;
- comparing the said abundance of said patient with the abundance of said *Dialister* spp. in said biological sample of a control subject;
- if said abundance for said patient is at least 10%, at least 20%, at least 30%, at least 40%, at least
25 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100% higher or at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold higher or between 2-fold and 10-fold higher or between 3-fold and 7-fold higher than the abundance of said *Dialister* spp. in said biological sample of a control subject without said inflammatory arthritis disease, then concluding that said patient has or is at risk of developing said inflammatory arthritis disease.

30 In a particular embodiment, said *Dialister* spp. is a *Dialister* spp. that comprises a 16S rRNA sequence with an at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 100% identity to one of the 16S rRNA sequences listed in Table 4. In a more particular embodiment, said

Dialister spp. is *Dialister succinatiphilus*, *Dialister invisus*, *Dialister propionifaciens*, *Dialister micraerophilus* or *Dialister pneumosintes*. In an even more particular embodiment, said *Dialister* spp. is a *Dialister* OTU listed in Table 4. In an even more particular embodiment, said *Dialister* spp. is OTU44, OTU60 or OTU62 as listed in Table 4.

- 5 Preferably, the abundance of a *Dialister* spp. is determined by 16S rRNA sequencing as explained above. However, detecting the presence and determining the abundance can also be performed indirectly by determining metabolic products or proteins which are produced specifically by said *Dialister* spp.

In a particular alternative of all above embodiments and provided methods, said inflammatory arthritis is spondyloarthritis.

- 10 Another aspect of the application is to provide methods for developing a suitable treatment for patients with inflammatory arthritis or more particular with spondyloarthritis. The methods involve determining a gut microbiome profile using a biological sample from the patient as described herein, and interpreting the profile by correlating the results with the presence and/or likelihood of developing a condition of interest associated with inflammatory arthritis or more particular spondyloarthritis. Conditions of
15 interest that can be detected, confirmed, or prognosticated using this method include but are not limited to joint or gut inflammation. Once such an analysis has been completed, it will encourage and delineate paths for suitable therapy developed or designed to combat, treat, lessen symptoms of, etc. the conditions that are identified. Upon treatment, the microbial profile will change and be able to predict response to therapy for inflammatory arthritis such as spondyloarthritis and/or for joint or gut
20 inflammation. Preferably, a biological therapy is used, and includes, but is not limited to, TNF-alpha blockers, anti-IL17A monoclonal antibodies, amongst others.

In one embodiment, a method is provided to design a treatment for an inflammatory arthritis disease in a patient, comprising the steps of:

- determining the abundance of *Dialister* spp. in a biological sample of said patient;
- 25 - if said abundance for said patient is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100% higher or at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold higher or between 2-fold and 10-fold higher or between 3-fold and 7-fold higher than the abundance of said *Dialister* spp. in said biological sample of a control subject without said inflammatory arthritis disease, then selecting an
30 appropriate treatment, and treating said patient according to said selected treatment.

Preferably, a biological therapy is used, and includes, but is not limited to, TNF-alpha blockers, anti-IL17A monoclonal antibodies, amongst others.

In a particular alternative of above embodiments and provided methods, said inflammatory arthritis is spondyloarthritis.

5 Another aspect of the application is to provide methods for monitoring the efficacy of a treatment that is treating a condition or complication associated with inflammatory arthritis or more particularly spondyloarthritis. The method involves determining gut microbiome profiles of a patient who is or who is going to be treated for inflammatory arthritis or for a condition or complication of interest associated with inflammatory arthritis, e.g. joint and/or gut inflammation. Multiple profiles are generally obtained
10 and analyzed at suitable time intervals, e.g. just prior to treatment to establish a baseline, and then repeatedly every few days, weeks or months thereafter. Subsequent profiles are compared to suitable reference profiles and/or to one or more previous profiles from the patient. If subsequent profiles indicate that the patient's gut microbiome profile is improving (e.g. is more similar to that of controls who do not have the condition of interest, especially when compared to previous patient signatures)
15 then the treatment may be continued without adjustment, or may be gradually decreased, and may even be discontinued. However, if no improvement is observed, or if a signature indicates a worsening of the condition, then the treatment protocol can be adjusted accordingly, e.g. more of a treatment agent may be administered, or a different and/or more drastic form of treatment may be implemented, etc. The gut microbiome profile is thus used to assess treatment adequacy and treatment response after
20 therapies such as those available for inflammatory arthritis or more particularly spondyloarthritis.

This is equivalent as saying that methods are provided to monitor the efficacy of a treatment in a patient with an inflammatory arthritis disease, said method comprising the steps of:

- determining a gut microbiome profile for said patient, said gut microbiome profile comprising an indication of the presence and/or relative abundance of at least *Dialister* spp.;
- 25 – comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles, wherein said one or more gut microbiome reference profiles comprise one or more of a positive gut microbiome reference profile based on results from control subjects with said inflammatory arthritis disease and a negative gut microbiome reference profile based on results from control subjects without said inflammatory arthritis disease;
- 30 wherein a gut microbiome profile for said patient that statistically significantly matches said negative gut microbiome reference profile is indicative for an efficacious treatment; and

wherein said analyzing and comparing steps are performed at one or more successive time points with biological samples collected from said patient at one or more successive time periods during said treatment.

In one embodiment, the application also provides methods to monitor the efficacy of a treatment for joint inflammation in a patient with an inflammatory arthritis disease, said method comprising the steps of:

- determining a gut microbiome profile for said patient, said gut microbiome profile comprising an indication of the presence and/or relative abundance of at least *Dialister* spp.;
- comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles, wherein said one or more gut microbiome reference profiles comprise one or more of a positive gut microbiome reference profile based on results from control subjects with joint inflammation and a negative gut microbiome reference profile based on results from control subjects without joint inflammation;

wherein a gut microbiome profile for said patient that statistically significantly matches said negative gut microbiome reference profile is indicative for an efficacious treatment; and

wherein said analyzing and comparing steps are performed at one or more successive time points with biological samples collected from said patient at one or more successive time periods during said treatment.

In another embodiment, the application also provides methods to monitor the efficacy of a treatment for gut inflammation in a patient with an inflammatory arthritis disease, said method comprising the steps of:

- determining a gut microbiome profile for said patient, said gut microbiome profile comprising an indication of the presence and/or relative abundance of at least *Dialister* spp.;
- comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles, wherein said one or more gut microbiome reference profiles comprise one or more of a positive gut microbiome reference profile based on results from control subjects with gut inflammation and a negative gut microbiome reference profile based on results from control subjects without gut inflammation;

wherein a gut microbiome profile for said patient that statistically significantly matches said negative gut microbiome reference profile is indicative for an efficacious treatment; and

wherein said analyzing and comparing steps are performed at one or more successive time points with biological samples collected from said patient at one or more successive time periods during said treatment.

In another embodiment, a method is provided to monitor the efficacy of a treatment for an inflammatory arthritis disease in a patient, said method comprising the steps of:

- determining the abundance of a *Dialister* spp. in a biological sample of said patient at two or more successive time points with biological samples collected from said patient at two or more successive time periods during said treatment;
- if the abundance of said *Dialister* spp. for said patient at a later time point of said two or more successive time points is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% lower than the abundance of said *Dialister* spp. at an earlier time point of said two or more successive time points, then concluding that said treatment is efficacious.

In another embodiment, a method is provided to monitor the efficacy of a treatment for joint and/or gut inflammation in a patient with an inflammatory arthritis disease, said method comprising the steps of:

- determining the abundance of a *Dialister* spp. in a biological sample of said patient at two or more successive time points with biological samples collected from said patient at two or more successive time periods during said treatment;
- if the abundance of said *Dialister* spp. for said patient at a later time point of said two or more successive time points is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% lower than the abundance of said *Dialister* spp. at an earlier time point of said two or more successive time points, then concluding that said treatment is efficacious.

Preferably, a biological therapy is used, and includes, but is not limited to, TNF-alpha blockers, anti-IL17A monoclonal antibodies, amongst others.

In a particular alternative of above embodiments and provided methods, said inflammatory arthritis is spondyloarthritis.

Another aspect of the application is to provide methods of assessing the disease activity or a change in disease activity in a patient suffering from or at risk of developing an inflammatory arthritis disease or more particular spondyloarthritis. The method involves determining a gut microbiome profile of such patients at one time point. Otherwise, if the objective is to assess a change in disease activity, multiple profiles may be obtained and analyzed at suitable time intervals, e.g. at a very early stage of the disease, or at a later stage of the disease. Subsequent profiles are compared to suitable reference profiles that are characteristic for a different stage of the disease and/or to one or more previous profiles from the

patient. If the patient's gut microbiome profile statistically significantly matches a gut microbiome reference profile that is characteristic for a particular stage of the disease, then a particular disease activity score is obtained. If comparison with one or more previous profiles from the patient indicates the patient's gut microbiome profile is improving or worsening, then a change in disease activity score is obtained for the disease.

Accordingly, provided herein is a method of assessing the disease activity or a change in the disease activity in a patient suffering from or at risk of developing an inflammatory arthritis disease, said method comprising the steps of:

- determining a gut microbiome profile for said patient, wherein said gut microbiome profile comprises an indication of the presence and/or relative abundance of at least *Dialister* spp., and comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles each characteristic for a different stage of the disease, wherein said one or more gut microbiome reference profiles are based on results from control subjects that are characterized by different disease activities of said inflammatory arthritis disease; and
- if said gut microbiome profile for said patient statistically significantly matches said one or more gut microbiome reference profile each characteristic for a different stage of the disease, then a disease activity score or a change in disease activity score is obtained for said inflammatory arthritis.

Another aspect of the application is the use of a gut microbiome profile to detect the presence or to assess the risk of development of an inflammatory arthritis disease, or to assess disease activity in a patient with an inflammatory arthritis disease, wherein said gut microbiome profile comprises an indication of the presence and/or abundance of at least *Dialister* spp. In one embodiment, the use is provided of a gut microbiome profile to detect the presence or to assess the risk of development of joint and/or gut inflammation in a patient with an inflammatory arthritis disease, wherein said gut microbiome profile comprises an indication of the presence and/or abundance of at least *Dialister* spp.

In a particular alternative of the above embodiments and provided methods, said inflammatory arthritis is spondyloarthritis.

Another aspect of the application encompassed a kit for carrying out any of the methods as described in current application. These kits preferably comprise devices and reagents for determining a gut microbiome profile as described herein, and/or devices and reagents for determining the abundance of the *Dialister* spp. of the current application in a biological sample and instructions and reference material for performing the analysis.

Another aspect of the application, is to provide methods of treating an inflammatory arthritis disease, said method comprising:

- determining a gut microbiome profile for said patient, said gut microbiome profile comprising an indication of the presence and/or relative abundance of at least *Dialister* spp.;
- 5 - comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles, wherein said one or more gut microbiome reference profiles comprise at least one of a positive gut microbiome reference profile based on results from control subjects with said inflammatory arthritis disease and a negative gut microbiome reference profile based on results from control subjects without said inflammatory arthritis disease,
- 10 - administering anti-inflammatory therapy to said patient, if said gut microbiome profile for said patient statistically significantly matches said positive gut microbiome reference profile.

In one embodiment, methods are provided of treating gut inflammation in a patient with inflammatory arthritis, said method comprising:

- determining a gut microbiome profile for said patient, said gut microbiome profile comprising an indication of the presence and/or relative abundance of at least *Dialister* spp.;
- 15 - comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles, wherein said one or more gut microbiome reference profiles comprise at least one of a positive gut microbiome reference profile based on results from control subjects with gut inflammation and a negative gut microbiome reference profile based on results from control
- 20 subjects without gut inflammation,
- administering anti-inflammatory therapy to said patient, if said gut microbiome profile for said patient statistically significantly matches said positive gut microbiome reference profile.

In another embodiment, methods are provided of treating joint inflammation in a patient with inflammatory arthritis, said method comprising:

- 25 - determining a gut microbiome profile for said patient, said gut microbiome profile comprising an indication of the presence and/or relative abundance of at least *Dialister* spp.;
- comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles, wherein said one or more gut microbiome reference profiles comprise at least one of a positive gut microbiome reference profile based on results from control subjects with joint
- 30 inflammation and a negative gut microbiome reference profile based on results from control subjects without joint inflammation,
- administering anti-inflammatory therapy to said patient, if said gut microbiome profile for said patient statistically significantly matches said positive gut microbiome reference profile.

In other particular embodiment, methods are provided to treat an inflammatory arthritis disease or joint inflammation in a patient with inflammatory arthritis, said method comprising:

- determining the abundance of *Dialister* spp. in a biological sample of said patient;
- administering anti-inflammatory therapy to said patient, if said abundance for said patient is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100% higher or at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold higher or between 2-fold and 10-fold higher or between 3-fold and 7-fold higher than the abundance of said *Dialister* spp. in said biological sample of a control subject without said inflammatory arthritis disease or without joint inflammation.

10 In other particular embodiment, methods are provided to treat gut inflammation in a patient with inflammatory arthritis, said method comprising:

- determining the abundance of *Dialister* spp. in a biological sample of said patient;
- administering anti-inflammatory therapy to said patient, if said abundance for said patient is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100% higher or at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold higher or between 2-fold and 10-fold higher or between 3-fold and 7-fold higher than the abundance of said *Dialister* spp. in said biological sample of a control subject without gut inflammation.

20 In particular embodiments, said anti-inflammatory therapy includes a biological therapy, such as TNF-alpha blockers, anti-IL17A monoclonal antibodies.

In a particular extension of all embodiments of above described aspects and of all embodiments in current application, said at least *Dialister* spp. comprises one or more *Dialister* spp. that comprise a 16S rRNA sequence with an at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 100% identity to a 16S rRNA sequence selected from Table 4. In another particular extension of all embodiments of above described aspects and of all embodiments in current application, said at least *Dialister* spp. comprises at least *Dialister succinatiphilus*, *Dialister invisus*, *Dialister propionifaciens*, *Dialister micraerophilus* or *Dialister pneumosintes*. In another particular extension of all embodiments of above described aspects and of all embodiments in current application, said at least *Dialister* spp. comprises one or more *Dialister* OTUs listed in Table 4. In another particular extension of all 30 embodiments of above described aspects and of all embodiments in current application, said at least *Dialister* spp. comprises at least OTU44, OTU60 or OTU62 as specified in Table 4.

In a particular extension of all embodiments of above described aspects and of all embodiments in current application, said *Dialister* spp. is a *Dialister* spp. that comprises a 16S rRNA sequence with an at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 100% identity to one of the 16S rRNA sequences listed in Table 4. In a more particular extension of all embodiments of
5 above described aspects and of all embodiments in current application, said *Dialister* spp. is *Dialister succinatiphilus*, *Dialister invisus*, *Dialister propionifaciens*, *Dialister micraerophilus* or *Dialister pneumosintes*. In an even more particular extension of all embodiments of above described aspects and of all embodiments in current application, said *Dialister* spp. is a *Dialister* OTU listed in Table 4. In an even more particular extension of all embodiments of above described aspects and of all embodiments
10 in current application, said *Dialister* spp. is OTU44, OTU60 or OTU62 as specified in Table 4.

In a most particular extension of all embodiments of above described aspects and embodiments in current application, said gut inflammation is not Crohn's disease.

The following examples are intended to promote a further understanding of the invention. While the invention is described herein with reference to illustrated embodiments, it should be understood that
15 the invention is not limited hereto. Those having ordinary skill in the art and access to the teachings herein will recognize additional modifications and embodiments within the scope thereof. Therefore, the invention is limited only by the claims attached herein.

EXAMPLES

Example 1. Patient characteristics for biopsies

20 Mucosal samples from 27 SpA patients and 15 healthy controls were used. Patient characteristics at baseline according to bowel histology are summarized in Table 1. Consistent with earlier reports, chronic inflammation was associated with younger age and male sex ($p=0.010$ and $p=0.021$, respectively). None of the other clinical characteristics (BMI, symptom duration, CRP, BASDAI, ASDAS, HLAB27, AS versus non-radiographic axial SpA, smoking status) were significantly associated with bowel histology. There
25 was also no significant difference in NSAID index.

Example 2. Microbial composition and diversity across biopsy samples

We first assessed overall variation of microbial composition and diversity across samples. Microbial diversity comprises richness (observed species; here measured by observed OTU richness, Figure 1a) and evenness (how the relative abundance or biomass is distributed among species); these combined
30 properties are measured by the Shannon Diversity index, Figure 1b. Whole sample community

composition-based ordination on Bray Curtis distances did not show clear sample separation based on biopsy location (Figure 1c). Likewise no significant differences in richness and evenness of colonic and ileal biopsies were detected. Overall, bacterial profiles of ileum and colon were more similar within one individual than same-site samples across persons. However, all further analyses were performed on either ileal or colonic samples, using only one biopsy sample per patient. Given the overall low bacterial yield from biopsy samples, we next assessed any interference from contaminant bacteria. To this aim, we analysed the bacterial profile of negative controls (blanks; see methods). Negative controls exhibit a profile dominated by genera belonging to the phylum Proteobacteria, which represents a minor contributor to the profile of our biopsies. The profile of gut microbiota reported in this study is consistent with the general profile of the human gut microbiome, dominated by Firmicutes and Bacteroidetes. These results rule out any major contamination event during the generation of molecular data.

Example 3. Intestinal inflammation versus microbial diversity and composition in biopsy samples

Inflamed ileum and colon biopsies presented significantly higher Shannon Diversity Index (evenness) compared to non-inflamed samples (ileum $p=0.030$ and colon $p=0.025$). Also, a trend towards greater microbial richness was observed in inflamed versus non-inflamed biopsies (Figure 2 + Figure 8). Microbial richness was higher in chronically inflamed versus acute or non-inflamed biopsies. After performing non-parametric Welch Two Sample t-test with 1000 permutations and multiple testing corrections, a significant difference in richness between acute and chronically inflamed ileal biopsies was observed ($p=0.009$, FDR-corrected q -value of 0.027). Likewise, for ileal biopsies a trend of positive association between the type of inflammation and microbial evenness was found, with higher evenness in acutely inflamed biopsies, followed by chronic inflamed biopsies and lower levels in non-inflamed and healthy control biopsies (Figure 2 + Figure 8). We also assessed the effect of systemic inflammation on microbial diversity, but found no significant link between CRP levels and diversity measurements. Next, we assessed whether overall bacterial community composition was associated with gut histology. A PCoA on Bray-Curtis dissimilarity showed mild separation by inflammation status, which was confirmed by permutational multivariate analysis of variance (PERMANOVA) (p -value of 0.016 and 0.011 for ileum and colon respectively; Figure 3 and 4). Hierarchical clustering on Bray-Curtis distances revealed that inflamed ileal biopsies (acute and chronic) formed a cluster separated from non-inflamed biopsies (Figure 3). Observations in colonic biopsies were highly consistent with those in the ileal biopsies (Figure 4). In conclusion, our results indicate a significant difference in intestinal microbial composition in SpA patients with and without microscopic gut inflammation.

Example 4. *Dialister*, a potential microbial marker of disease activity in SpA patients

To further explore the relationship between bacterial composition and inflammation, we tested which bacterial genera were significantly associated with gut histology. However, no specific genus was significantly correlated with gut inflammation (Table 2 and 3). Next, we examined a possible link between bacterial composition and disease activity parameters. We observed a positive correlation between the abundance of the genus *Dialister* and ASDAS (FDR-corrected q-value of 0.026) (Figure 5a; results are given for ileal biopsies). A positive correlation between *Dialister* and BASDAI and CRP was also found. Results were consistent between acute and chronic inflammation, but the association between *Dialister* and ASDAS was most pronounced in chronically inflamed biopsies (Figure 5b). In colonic biopsies, a consistent correlation was observed (Figure 6) as expected given the high concordance between *Dialister* abundances in colonic and ileal samples (Figure 7). (Nonparametric) t-test analysis revealed that abundance of *Dialister* was significantly higher in ileal and colonic biopsies from the inflamed versus non-inflamed and healthy control groups (FDR < 0.10), with higher abundance seen in acutely inflamed biopsies (Figure 9). More precisely, for ileal biopsies, we observed a 3.5 fold increase in the abundance of *Dialister* in inflamed biopsies from SpA patients compared to healthy controls and a 1.3 fold increase in the abundance of *Dialister* in non-inflamed biopsies from SpA patients compared to healthy controls. Still for ileal biopsies, we observed a 5.1, 2.6 and 1.3 fold increase in the abundance of *Dialister* in acute, chronic and non-inflamed biopsies respectively from SpA patients compared to healthy controls. For colonic biopsies, we observed a 6.8 and 1.9 fold increase in abundance of *Dialister* in inflamed and non-inflamed biopsies respectively from SpA patients compared to healthy controls. For colonic biopsies, we also observed a 5.8, 6.8 and 1.9 fold increase in the abundance of *Dialister* in acute chronic and non-inflamed biopsies respectively from SpA patients compared to healthy controls. We also found a trend for higher levels of specific genera that have previously been reported to be associated with inflammation (i.e. *Prevotella* (Scher et al. 2013, eLife;2:e01202) in the inflamed (chronic and acute) biopsies. In conclusion, we identified *Dialister* as a potential microbial marker of disease activity.

To further understand the *Dialister* microbiome composition, we performed a phylogenetic study of several *Dialister* OTUs (operational taxonomic units) which are high-abundant in biopsy samples of SpA patients or in stool samples of persons that volunteered in the Flemish Gut Flora project (FGFP). More precisely, a phylogenetic analysis was performed using the maximum likelihood method based on partial 16S rRNA gene sequences encompassing 250 positions corresponding to the V4-16S rDNA region, thus covering app. 15% of the 16S rRNA gene. The FGFP is a large-scale cross-sectional fecal sampling effort in a confined geographical region, more precisely Flanders (Belgium). The FGFP cohort is expected to be representative for the average gut microbiota composition in a Western European population (Falony et al 2016 Science 352: 560-564). Surprisingly, a clear difference was found between SpA samples and FGFP

samples. OTU60 and OTU62 were the most abundant *Dialister* OTUs in SpA patients. Both OTUs had a 100% identical nucleotide sequence (based on 250 positions of V4-16S rDNA) to *D. invisus*. The most abundant *Dialister* OTUs in FGFP samples were OTU4552 that shows highest similarity to *D. micraerophilus*, OTU6938 that shows highest similarity to *D. succinatiphilus*, OTU1378 that does not
5 show high similarity to a known *Dialister* species, and OTU605 and OTU233 that both show highest similarity to *D. invisus*.

Example 5. *Dialister* OTU distribution in stool samples of SpA patients

Following up on the *Dialister* results regarding colonic and ileal mucosa, we examined stool samples from SpA patients with different levels of ASDAS (Ankylosing Spondylitis Disease Activity Score), NSAID
10 (Nonsteroidal anti-inflammatory drug), BASDAI (Bath Ankylosing Spondylitis Disease Activity Index), Inflammation activity and fecal calprotectin. Characteristics of the SpA patients are summarized in Table 5. Bacteria profiling from 46 stools samples was characterized using the methods described in this application. Sequences were quality trimmed, demultiplexed, analyzed and taxonomy identified against RDP/Greengenes database using LotuS. All reads per sample were used for *Dialister* abundance analysis.
15 The rest of the analysis was performed using R libraries on data rarefied at 10000 observations/reads per sample. Using all reads, *Dialister* is present in 74% of the stools samples from SpA patients (35 of 46 patients), with an abundance ranging from 3.3E-17 to 7.7% (Figure 10). From the 16 different OTUs assigned to the genus *Dialister*, OTU 44 is the main contributor, followed by OTU 515, OTU 420 and OTU 685. Similar to the most abundant OTU in biopsy samples (see Example 4), OTU 44 exhibits a sequence
20 match of 100% to *Dialister invisus*. The other OTUs cannot be reliably assigned to a known *Dialister* species based on what is available so far in NCBI.

Example 6. Correlation between *Dialister* abundance in stool samples and ASDAS

The studied stool samples (n=46 stool samples from patients with SpA) exhibit a positive correlation between *Dialister* and ASDAS. This correlation is improved when samples are grouped by gut
25 inflammation status (normal vs. inflamed biopsies). The positive correlation value of 0.13 for all stool samples can be divided in 0.29 for patients with inflammation and -0.04 for patients without inflammation. This pattern is consistent with our results of *Dialister* abundance in colonic and ileal mucosa, but it is not significant (Figure 11). The correlation is driven by OTU 44, which is the most abundant OTU assigned to the *Dialister* genus (Figure 10).

Example 7. Correlation between *Dialister* abundance in stool samples and NSAID

Dialister abundance positively correlates with levels of intake of non-steroidal anti-inflammatory drugs (Figure 12, $\rho=0.34$, $p < 0.01$), thus further building evidence for a clear link between *Dialister* abundance and SpA. In conclusion, the data presented in Examples 5-7 clearly show that the positive correlation between *Dialister* abundance and SpA can also be observed in stool samples. These surprising findings are of great importance for the diagnosis of SpA and other inflammatory arthritis diseases, since these data show that inflammatory arthritis disease can be detected or diagnose using non-invasive sampling techniques.

Example 8. *Dialister* abundance in oral samples is correlated with SpA

Bisanz et al, 2016 (The oral microbiome of patients with axial spondyloarthritis compared to healthy individuals; *Peer J* 4:e2095) compares the oral microbiome of patients with axial spondyloarthritis (AxSpA) with healthy individuals and did not find strong evidence of any single taxa associated with AxSpA in the sub gingival plaque. After performing reanalysis of the data, and looking for genera enriched or depleted in these two groups, we confirmed their finding, not finding significant differences in the abundance between groups. However, the AxSpA group exhibits a higher mean abundance of *Dialister*, consistent with our findings in stool samples in the colonic and ileal mucosa (Figure 13). These data thus further broaden the scope of samples that can be used to diagnose inflammatory arthritis diseases in a patient. Beside invasive techniques such as biopsy, also samples obtained by non-invasive sampling techniques (stool, oral plaques) can be used.

METHODS TO THE EXAMPLES**Study Population and Sample Collection**

Mucosal samples from 27 SpA patients (Table 1) and 15 healthy controls were used. This study was conducted after approval by the ethical committee of Ghent University Hospital and written informed consent was obtained from all patients. Patients with overt IBD were excluded from this analysis, as were patients with prior exposure to biologic therapy, or use of conventional DMARDs (sulfasalazine, methotrexate, leflunomide), corticosteroids or antibiotics 2 months prior to ileocolonoscopy. NSAID intake 2 months prior to the ileocolonoscopy was estimated by calculation of the NSAID index score, as recommended by ASAS (Dougados et al. 2011, *Ann Rheum Dis* 70:249-251). Ileal and colonic biopsies were classified as normal or inflamed (acute/chronic) by an experienced pathologist. Biopsies used for nucleic acid extraction were kept at -80 °C in sterile cryovials.

Stool samples from 46 SpA patients (Table 5) were used. Patients were interviewed about their disease activity, drug intake and possible GI symptoms. A complete clinical examination was performed with scoring of tender and swollen joints, enthesitis and evaluation of axial mobility. Stool samples were collected within a week before colonoscopy (but prior to bowel preparation) and were stored
5 unprocessed at -80°C . At a later stage, 1g aliquots were prepared. Patients with significant GI symptoms or overt IBD were excluded from this analysis. Non-steroidal anti-inflammatory drug (NSAID) intake 3 months prior to the ileocolonoscopy was estimated by calculation of the NSAID index score, as proposed by the Assessment of SpondyloArthritis international Society (ASAS).

10 **Nucleic acid extraction**

A total of 54 biopsy samples, with associated clinical information, (27 colonic and 27 ileal) from SpA patients and 21 biopsy samples from healthy controls (15 ileal and 6 colonic) and a total of 46 stool samples, with associated clinical information from SpA patients were used for this study (Table 1 and 5). DNA was extracted from biopsies and stool samples using the PowerMicrobiome[®] RNA Isolation Kit (MO
15 BIO Laboratories Inc., Carlsbad, CA) following manufacturer's instructions, with the addition of 10 minutes at 90°C before vortexing and with the exclusion of the DNase I step. No more than 11 samples were prepared at the time and each set of extractions included a negative control (blank). All steps were performed under a biohazard type II cabinet and all material was decontaminated using UVC light. Surfaces and gloves were decontaminated using RNase AWAY[®] (Molecular Bio-Products Inc., San Diego,
20 CA).

16S rRNA profiling and analysis

To amplify the variable region 4 (V4) of the 16S rRNA gene, we used the 515F and 806R primers (GTGCCAGCMGCCGCGGTAA (SEQ ID NO. 25) and GGACTACHVGGGTWTCTAAT (SEQ ID NO. 26) respectively) modified to contain Illumina adapters and barcode sequences to allow for directional
25 sequencing (Caporaso et al. 2011, Proc Natl Acad Sci USA, 108 Suppl 1:4516-4522). Sequencing was performed on the Illumina MiSeq platform (MiSeq Reagent Kit v2, 500-cycles, 20% PhiX) according to the manufacturer's specifications to generate paired-end reads of 250 bases in length in each direction. The overlapping paired-end reads were merged using fastq-join (Aronesty et al. 2013, Open Bioinforma J 7:1-8) and processed with LotuS pipeline (Hildebrand et al. 2014, Microbiome 2:30), clustering sequences
30 into OTUs using Greengenes 2013 database for taxonomy assignment. Further analysis was performed in a subset of the data rarefied at 25000 and 20000 observations per sample using phyloseq (McMurdie et al. 2012, Pacific Symposium on Biocomputing 235-246) and R scripts.

Statistical Analysis

Statistical significance was evaluated using non-parametric Welch Two Sample t-test with 1000 permutations, Mann-Whitney-Wilcoxon Test, Kruskal-Wallis H-test (non-parametric ANOVA) and Spearman rank correlation tests as specified throughout the results. The significance threshold was set at 0.05. Permutational Multivariate analysis of variance (PERMANOVA) was conducted with the vegan functions adonis using 10000 permutations. Correction for multiple testing (q-values) was performed by applying the Benjamini-Hochberg False Discovery Rate (FDR) approach. PERMANOVA and Kruskal-Wallis H-test were performed on filtered OTUs matrices for ileum and colon after removing OTUs with absolute abundance lower than 0.01%.

10

TABLES

Table 1. Clinical characteristics of the SpA patients at baseline for the biopsy samples. For numerical variables, the first number is the mean with between parentheses the minimum and maximum values. NSAID index was calculated for 2 months preceding ileocolonoscopy. F: female, M: male, AS: Ankylosing Spondylitis, nr-axSpA: non-radiographic axial spondyloarthritis, BMI: Body mass index, CRP: C-reactive protein, BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, ASDAS: Ankylosing Spondylitis Disease Activity Score, N: non-smoker, F: former smoker and C: current smoker. NSAIDs: non-steroidal anti-inflammatory drugs.

15

	Normal histology	Acute inflammation	Chronic inflammation
	(N = 13)	(N = 5)	(N = 9)
Sex	10F, 3M	1F, 4M	3F, 6M
Age (years)	39 (10-56)	37 (26-50)	28 (17-40)
Diagnosis	6 AS, 7 nr-axSpA	2 AS, 3 nr-axSpA	6 AS, 3 nr-axSpA
BMI	25 (19-32)	25 (20-31)	27 (22-39)
Symptom Duration (years)	10 (0.5-31.1)	8.7 (0.2-27)	6.1 (0.7-13)
CRP (mg/dL)	0.8 (0-2.4)	1 (0.2-2.6)	0.8 (0.1-1.7)
BASDAI	4.3 (1.4-7.4)	5 (2.4-9.6)	4.4 (0.4-6.5)
ASDAS	2.6 (0.7-3.9)	3.1 (1.6-5.4)	3 (0.95-4.2)
HLA-B27	10(+)3(-)	5(+) 0(-)	8(+) 1(-)

	Normal histology	Acute inflammation	Chronic inflammation
	(N = 13)	(N = 5)	(N = 9)
Smoking status	8N, 1F, 4C	2N, 1F, 2C	4N, 1F, 4C
NSAID index (%)	47 (0-100)	43 (32-57)	67 (38-100)

Table 2. Kruskal-Wallis H-test on ileal genera abundance and histological inflammation groups. "p" is the raw p- value and "q" is the p-value corrected by the Benjamini-Hochberg False Discovery Rate procedure for multiple comparisons.

Phylum	Genera	p	q	Non inflamed	Chronic	Acute
Firmicutes	<i>Blautia</i>	0.003	0.152	0.084	0.265	0.129
Bacteroidetes	<i>Odoribacter</i>	0.009	0.168	0.000	0.002	0.002
Firmicutes	<i>Oscillospira</i>	0.011	0.168	0.001	0.004	0.002
Actinobacteria	<i>Collinsella</i>	0.026	0.303	0.002	0.005	0.002
Bacteroidetes	<i>Prevotella</i> (Prevotellaceae)	0.046	0.428	0.007	0.034	0.046
Firmicutes	<i>Alicyclobacillus</i>	0.068	0.521	0.002	0.003	0.008
Proteobacteria	<i>Desulfavibrio</i>	0.078	0.521	0.002	0.004	0.001
Bacteroidetes	<i>Bacteroides</i>	0.100	0.575	0.204	0.118	0.087
Proteobacteria	<i>Pseudomonas</i>	0.110	0.575	0.003	0.004	0.007
Proteobacteria	<i>Bradyrhizobium</i>	0.133	0.624	0.003	0.003	0.006
Firmicutes	<i>Ruminococcus</i>	0.157	0.669	0.174	0.110	0.088
Proteobacteria	<i>Methylobacterium</i>	0.177	0.694	0.010	0.026	0.023
Firmicutes	Clostridiales_genus	0.213	0.758	0.012	0.017	0.014
Firmicutes	<i>Ruminococcus</i>	0.239	0.758	0.003	0.005	0.002
Bacteroidetes	<i>Parabacteroides</i>	0.270	0.758	0.007	0.007	0.003
Proteobacteria	Enterobacteriaceae_genus	0.285	0.758	0.024	0.006	0.032
Verrucomicrobia	<i>Akkermansia</i>	0.286	0.758	0.002	0.000	0.000
Firmicutes	<i>Faecalibacterium</i>	0.290	0.758	0.042	0.068	0.077
Firmicutes	<i>Acidaminococcus</i>	0.364	0.763	0.002	0.002	0.000
Firmicutes	<i>Dialister</i>	0.366	0.763	0.002	0.004	0.004
Firmicutes	Clostridiaceae_genus	0.378	0.763	0.001	0.001	0.002
Firmicutes	<i>Gemella</i>	0.379	0.763	0.003	0.000	0.001
Bacteroidetes	Rikenellaceae_genus	0.387	0.763	0.004	0.001	0.007
Bacteroidetes	<i>Prevotella</i> (Paraprevotellaceae)	0.390	0.763	0.000	0.000	0.018
Firmicutes	Lachnospiraceae_genus	0.461	0.783	0.033	0.040	0.034
Proteobacteria	<i>Actinobacillus</i>	0.461	0.783	0.000	0.000	0.021
Firmicutes	Ruminococcaceae_genus	0.469	0.783	0.018	0.028	0.028
Firmicutes	<i>Eubacterium</i>	0.487	0.783	0.011	0.016	0.051
Actinobacteria	<i>Actinomyces</i>	0.534	0.783	0.002	0.001	0.002
Firmicutes	<i>Peptostreptococcus</i>	0.536	0.783	0.001	0.000	0.002
Firmicutes	<i>Dorea</i>	0.539	0.783	0.029	0.014	0.018
Firmicutes	<i>Lachnospira</i>	0.546	0.783	0.004	0.001	0.002
Firmicutes	<i>SMB53</i>	0.558	0.783	0.041	0.000	0.001
Firmicutes	Erysipelotrichaceae_genus	0.566	0.783	0.011	0.006	0.003
Firmicutes	<i>Veillonella</i>	0.635	0.853	0.001	0.001	0.001
Firmicutes	<i>Streptococcus</i>	0.703	0.918	0.011	0.015	0.019
Firmicutes	Peptostreptococcaceae_genus	0.750	0.936	0.017	0.003	0.000
Proteobacteria	<i>Haemophilus</i>	0.764	0.936	0.004	0.005	0.031
Proteobacteria	<i>Bilophila</i>	0.786	0.936	0.004	0.002	0.003
Firmicutes	<i>Roseburia</i>	0.822	0.936	0.018	0.010	0.028
Proteobacteria	<i>Sutterella</i>	0.824	0.936	0.009	0.007	0.005
Firmicutes	<i>Parvimonas</i>	0.836	0.936	0.001	0.000	0.003
Bacteroidetes	Barnesiellaceae_genus	0.893	0.952	0.002	0.003	0.003
Firmicutes	<i>Granulicatella</i>	0.913	0.952	0.002	0.001	0.001
Firmicutes	<i>Coprococcus</i>	0.935	0.952	0.150	0.116	0.127
Actinobacteria	<i>Bifidobacterium</i>	0.942	0.952	0.003	0.018	0.002
Fusobacteria	<i>Fusobacterium</i>	0.952	0.952	0.020	0.005	0.032

Table 3. Kruskal-Wallis H-test on colonic genera abundance and histological inflammation groups. "p" is the raw p- value and "q" is the p-value corrected by the Benjamini-Hochberg False Discovery Rate procedure for multiple comparisons.

Phylum	Genera	p	q	Non inflamed	Chronic	Acute
Proteobacteria	<i>Desulfovibrio</i>	0.007	0.109	0.001	0.003	0.002
Firmicutes	<i>Blautia</i>	0.007	0.109	0.090	0.255	0.167
Bacteroidetes	<i>Prevotella</i> (Prevotellaceae)	0.008	0.109	0.005	0.042	0.045
Firmicutes	<i>Dialister</i>	0.054	0.489	0.001	0.004	0.005
Firmicutes	<i>Ruminococcus</i>	0.076	0.489	0.177	0.101	0.069
Firmicutes	<i>Streptococcus</i>	0.082	0.489	0.004	0.010	0.013
Spirochaetes	<i>Brachyspira</i>	0.088	0.489	0.000	0.003	0.009
Bacteroidetes	<i>Prevotella</i> (Pararevotellaceae)	0.104	0.491	0.000	0.000	0.022
Bacteroidetes	<i>Bacteroides</i>	0.113	0.491	0.186	0.100	0.099
Firmicutes	Clostridiales_genus	0.135	0.525	0.013	0.020	0.013
Bacteroidetes	<i>Odoribacter</i>	0.179	0.636	0.001	0.001	0.002
Actinobacteria	<i>Collinsella</i>	0.250	0.755	0.002	0.004	0.003
Firmicutes	<i>Oscillospira</i>	0.273	0.755	0.002	0.004	0.002
Firmicutes	Ruminococcaceae_genus	0.277	0.755	0.018	0.025	0.029
Firmicutes	<i>Acidaminococcus</i>	0.309	0.755	0.002	0.002	0.001
Proteobacteria	Enterobacteriaceae_genus	0.310	0.755	0.032	0.009	0.063
Firmicutes	<i>Faecalibacterium</i>	0.345	0.784	0.056	0.080	0.083
Firmicutes	<i>Coprococcus</i>	0.396	0.784	0.201	0.150	0.126
Bacteroidetes	<i>Parabacteroides</i>	0.402	0.784	0.006	0.006	0.004
Firmicutes	Lachnospiraceae_genus	0.402	0.784	0.036	0.043	0.035
Actinobacteria	<i>Bifidobacterium</i>	0.474	0.858	0.004	0.021	0.002
Firmicutes	<i>Ruminococcus</i>	0.484	0.858	0.004	0.004	0.002
Firmicutes	<i>Lachnospira</i>	0.537	0.899	0.003	0.002	0.002
Fusobacteria	<i>Fusobacterium</i>	0.553	0.899	0.010	0.004	0.019
Firmicutes	Peptostreptococcaceae_genus	0.638	0.981	0.001	0.004	0.000
Proteobacteria	<i>Haemophilus</i>	0.654	0.981	0.002	0.001	0.003
Firmicutes	<i>Dorea</i>	0.681	0.984	0.030	0.014	0.018
Proteobacteria	<i>Sutterella</i>	0.737	0.994	0.011	0.008	0.007
Firmicutes	<i>Eubacterium</i>	0.766	0.994	0.022	0.020	0.088
Proteobacteria	<i>Bilophila</i>	0.771	0.994	0.004	0.002	0.003
Bacteroidetes	Barnesiellaceae_genus	0.804	0.994	0.001	0.002	0.002
Cyanobacteria	YS2_genus	0.886	0.994	0.001	0.000	0.001
Proteobacteria	<i>Methylobacterium</i>	0.913	0.994	0.008	0.008	0.005
Bacteroidetes	Rikenellaceae_genus	0.924	0.994	0.004	0.001	0.004
Proteobacteria	<i>Pseudomonas</i>	0.945	0.994	0.004	0.003	0.002
Firmicutes	Erysipelotrichaceae_genus	0.953	0.994	0.013	0.007	0.005
Firmicutes	<i>Alicyclobacillus</i>	0.957	0.994	0.003	0.003	0.002
Firmicutes	<i>Roseburia</i>	0.980	0.994	0.021	0.011	0.021
Proteobacteria	<i>Bradyrhizobium</i>	0.994	0.994	0.003	0.002	0.002

Table 4. A selection of *Dialister* OTU's and their corresponding 16S rRNA fragments.

Dialister OTU	Highest similarity to	16S rRNA fragment	SEQ ID NO.
#OTU4552	<i>D. micraerophilus</i>	TACGTAGGTGGCAAGCGTTGTCCGGAATTATTGGGCG TAAAGCGCGCGCAGGCGGCTTCTAAGTCCATCTTAA AAGTGCAGGGGCTTAACCCCGTGATGGGATGGAACT GGGAGGCTGGAGTATCGGAGAGGAAAGTGGAAATCC TAGTGTAGCGGTGAAATGCGTAGAGATTAGGAAGAA CACCGGTGGCGAAGGCGACTTTCTGGACGACAACTGA CGCTGAGGCGCGAAAGCGTGGGGAGCAAACAGG	1
#OTU6938	<i>D. succinatiphilus</i>	TACGTAGGTGGCAAGCGTTGTCCGGAATTATTGGGCG TAAAGCGCGCGCAGGCGGCTTCTAAGTCCATCTTAA AAGTGCAGGGGCTTAACCCCGTGATGGGATGGAACT GGAAAGCTGGAGTATCGGAGAGGAAAGTGGAAATCC TAGTGTAGCGGTGAAATGCGTAGAGATTAGGAAGAA CACCGGTGGCGAAGGCGACTTTCTGGACGACAACTGA CGTTGAGGCACGAAAGCGTGGGTATCGAACAGG	2
#OTU1378	Uncultured <i>Dialister</i>	TACGTATGGTGCAAGCGTTGTCCGGAATTATTGGGCG TAAAGCGCGCGCAGGCGGCTTCTAAGTCCATCTTAA AAGTGCAGGGGCTTAACCCCGTGATGGGAAGGAACT GGGAAGCTGGAGTATCGGAGAGGAAAGTGGAAATCC TAGTGTAGCGGTGAAATGCGTAGAGATTAGGAAGAA CACCGGTGGCGAAGGCGACTTTCTGGACGAAACTG ACGCTGAGGCGCGAAAGCGTGGGGAGCAAACAGG	3
#OTU605	<i>Dialister invisus</i>	AACGTAGGTCACAAGCGTTGTCCGGAATTATTGGGCG TAAAGCGCGCGCAGGCGGCTTCCCAAGTCCCTCTTAA AAGTGCAGGGGCTTAACCCCGTGATGGGAAGGAACT GGGAAGCTGGAGTATCGGAGAGGAAAGTGGAAATCC TAGTGTAGCGGTGAAATGCGTAGAGATTAGGAAGAA CACCGGTGGCGAAGGCGACTTTCTGGACGAAACTG ACGCTGAGGCGCGAAAGCGTGGGG-AGCAAACAGG	4
#OTU233	<i>Dialister invisus</i>	TACGTAGGTGGCAAGCGTTGTCCGGAATTATTGGGCG TAAAGCGCGCGCAGGCGGCTTCCCAAGTCCCTCTTAA AAGTGCAGGGGCTTAACCCCGTGATGGGAAGGAACT GGGAAGCTGGAGTATCGGAGAGGAAAGTGGAAATCC TAGTGTAGCGGTGAAATGCGTAGAGATTAGGAAGAA CACCGGTGGCGAAGGCGACTTTCTGGACGAAACTG ACGCTGAGGCGCGAAAGTGCAGGATCGAACAGG	5
#OTU62	<i>Dialister invisus</i>	AGTGTACGCCCGCGGTAATACGTAGGTGGCAAGC GTTGTCCGGAATTATTGGGCGTAAAGCGCGCGCAGG CGGCTTCCCAAGTCCCTCTTAAAGTGCAGGGGCTTAA CCCCGTGATGGGAAGGAACTGGGAAGCTGGAGTAT CGGAGAGGAAAGTGGAAATCCTAGTGTAGCGGTGAA ATGCGTAGAGATTAGGAAGAACACCGGTGGCGAAGG CGACTTTCTGGACGAAACTGACGCTGAGGCGCGAAA GCGTGGGGAGCAAACAGG	6
#OTU60	<i>Dialister invisus</i>	ACGTAGGTGGCAAGCGTTGTCCGGAATTATTGGGCGT AAAGCGCGCGCAGGCGGCTTCCCAAGTCCCTCTTAA	7

Dialister OTU	Highest similarity to	16S rRNA fragment	SEQ ID NO.
		AGTGCGGGGCTTAACCCCGTGAGGGAAGGAACTGG GAAGCTGGAGTATCGGAGAGGAAAGTGGAAATCCTA GTGTAGCGGTGAAATGCGTAGAGATTAGGAAGAACA CCGGTGGCGAAGGCGACTTTCTGGACGAAAAGTAC GCTGAGGCGCGAAAGCGTGGGGAGCAAACAG	
#OTU373	Uncultured Dialister	ACGTAGGTGGCAAGCGTTGTCCGGAATTATTGGGCGT AAAGCGCGCGCAGGCGGCTTCCCAAGTCCCTCTTAAA AGTGCGGGGCTTAACCCCGTGATGGGAAGGAACTG GGAAGCTGGAGTATCGGAGAGGAAAGTGGAAATCCT AGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAAC ACCAAGTGGCGAAGGCGGCTTACTGGACAGTAACTGA CGTTGAGGCTCGAAAGCGTGGGGAGCAAACAG	8
#OTU_1251	<i>D. invisus</i>	CCTGTTTGCTCCCCACGCTTTCGTGCCTCAGTGTCAGT AGCAGTCCAGTAAGTCGCCTTCGCCACTGGTGTTCTC CTAATATCTACGCATTTACCGCTACACTAGGAATTCC ACTTACCTCTCCGATACTCCAGCTTCCCAGTTTCTTCC CATCACGGGGTTAAGCCCCGCACTTTTAAGAGGGACT TGGGAAGCCGCCTGCGCGCGCTTACGCCAATAATT CCGGACAACGCTTGCCACCTACGTA	9
# OTU_1303	<i>D. propionifaciens</i>	CCTGTTTGCTCCCCACGCTTTCGTGCCTCAGTGTCAGT AGCAGTCCAGTAAGTCGCCTTCGCCACTGGTGTTCTC CTAATCTCTACGCATTTACCGCTACACTAGGAATTCC ACTTTCCTCTCCGATACTCCAGCCTCTCAGTTTCCATCC CATCACGGGGTTAAGCCCCGCACTTTTAAGATGGACT TAAGAAGCCGCCTGCGCGCGCTTACGCCAATAATT CCGGACAACGCTTGCCACCTACGTA	10
# OTU_1459	Uncultured Dialister	CCTGTTTGCTCCCCACGCTTTCGCGCCTCAGCGTCAGT TTTCGTCCAGAAAGTCGCCTTCGCCACCGGTGTTCTTC CTAATATCTACGCATTTACCGCTACACTAGGAATTCC ACCTTCCTCTCCGATACTCCAGTCTCCCAGTTTCCATCC CCTCACGGGGTTAAGCCCCGCACTTCTAAGATAGACT TAAGAGACCGCCTGCGCGCGCTTACGCCAATAATT CCGGACAACGCTTGCCACCTACGTA	11
# OTU_2237	<i>D. invisus</i>	CCTGTTTCGCTCCCCTAGCTTTCGCGCCTCAGCGTCAGT GGCGGCCAGAAAGGCTGCCTTCGCCATCGGTGTTCTT CCCAATATCTGCGCATTTACCGCTACACTGGGAATTC CACTTTCCTCTCCGATACTCCAGCTTCCCAGTTTCTTCC CCATCACGGGGTTAAGCCCCGCACTTTTAAGAGGGAC TTGGGAAGCCGCCTGCGCGCGCTTACGCCAATAAT TCCGGACAACGCTTGCCACCTACGTA	12
# OTU_2284	<i>D. invisus</i>	CCTGTTTGATACCCACACTTTCGAGCCTCAATGTCAGT TGCAGCTTAGCAGGCTGCCTTCGCAATCGGAGTTCTTC GTGATATCTAAGCATTTACCGCTACACTAGGAATTCC ACTTTCCTCTCCGATACTCCAGCTTCCCAGTTTCTTCC CATCACGGGGTTAAGCCCCGCACTTTTAAGAGGGACT TGGGAAGCCGCCTGCGCGCGCTTACGCCAATAAT CCGGACAACGCTTGCCACCTACGTA	13

Dialister OTU	Highest similarity to	16S rRNA fragment	SEQ ID NO.
# OTU_2460	<i>D. invisus</i>	CCTGTTTGCTCCCCACACTTTCGCGCCTCAGCGTCAGT TACAGTCCAGTTAGTCGCCTTCGCCACTGGTGTTCCTC CCAATCTCTACGCATTTACCCGCTACACTGGGAATTCC ACTAACCTCTCCGATACTCCAGCTTCCCAGTTTCCTTCC CATCACGGGGTTAAGCCCCGCACTTTTAAGAGGGACT TGGGAAGCCGCCTGCGCGCGCTTTACGCCAATAATT CCGGACAACGCTTGCCACCTACGTA	14
# OTU_2494	<i>Dialister invisus</i>	CCTGTTTCGCTCCCCACGCTTTCGAGCCTCAGCGTCAGT TACAGACCAGAGAGCCGCTTTCGCCACCGGTGTTCTC CCATATATCTACGCATTTACCCGCTACACATGGAATTC CACTTTCCTCTCCGATACTCCAGCTTCCCAGTTTCCTTC CCATCACGGGGTTAAGCCCCGCACTTTTAAGAGGGAC TTGGGAAGCCGCCTGCGCGCGCTTTACGCCAATAAT TCCGGACAACGCTTGCCACCTACGTA	15
# OTU_361	<i>D. succinatiphilus</i>	CCTGTTTGCTCCCCACGCTTTCGCGCCTCAGCGTCAGT TGTCGTCCAGAAAGCCGCCTTCGCCACCGGTGTTCTTC CTAATCTCTACGCATTTACCCGCTACACTAGGAATTCC GCTTTCCTCTCCGATACTCCAGCTTTCAGTTTCCATCC CATCATGGGGTTAAGCCCCACGCTTTTAAGATGGACT TAAAGGGCCGCCTGCGCGCGCTTTACGCCAATAATT CCGGACAACGCTTGCCACCTACGTA	16
# OTU_420	<i>D. propionifaciens</i>	CCTGTTTGCTCCCCACGCTTTCGAGCCTCAGCGTCAGT TATCGTCCAGTAAGCCGCCTTCGCCACTGGTGTTCCTC CTAATATCTACGCATTTACCCGCTACACTAGGAATTCC ACTTTCCTCTCCGATACTCCAGCCTCTCAGTTTCCATCC CATCACGGGGTTAAGCCCCGCACTTTTAAGATGGACT TAAGAAGCCGCCTGCGCGCGCTTTACGCCAATAATT CCGGACAACGCTTGCCACCTACGTA	17
# OTU_44	<i>D. invisus</i>	CCTGTTTGCTCCCCACGCTTTCGCGCCTCAGCGTCAGT TTTCGTCCAGAAAGTGCCTTCGCCACCGGTGTTCTTC CTAATCTCTACGCATTTACCCGCTACACTAGGAATTCC ACTTTCCTCTCCGATACTCCAGCTTCCCAGTTTCCTTCC CATCACGGGGTTAAGCCCCGCACTTTTAAGAGGGACT TGGGAAGCCGCCTGCGCGCGCTTTACGCCAATAATT CCGGACAACGCTTGCCACCTACGTA	18
# OTU_497	<i>D. invisus</i>	CCTGTTTGCTCCCCACGCTTTCGAGCCTCAACGTCAGT TACCGTCCAGTAAGCCGCCTTCGCCACTGGTGTTCCTC CTAATATCTACGCATTTACCCGCTACACTAGGAATTCC GCTTACCTCTCCGATACTCCAGCTTCCCAGTTTCCTTCC CATCACGGGGTTAAGCCCCGCACTTTTAAGAGGGACT TGGGAAGCCGCCTGCGCGCGCTTTACGCCAATAATT CCGGACAACGCTTGCCACCTACGTA	19
# OTU_515	<i>D. propionifaciens</i>	CCTGTTTGCTACCCACACTTTCGTGCCTCAGCGTCAGT TGTCGTCCAGAAAGTGCCTTCGCCACCGGTGTTCTTC CTAATCTCTACGCATTTACCCGCTACACTAGGAATTCC ACTTTCCTCTCCGATACTCCAGCCTCCCAGTTTCCATCC CATCACGGGGTTAAGCCCCGCACTTTTAAGATGGACT	20

Dialister OTU	Highest similarity to	16S rRNA fragment	SEQ ID NO.
		TAAGAAGCCGCCTGCGCGCCTTTACGCCAATAATT CCGGACAACGCTTGCCACCTACGTA	
#OTU_685	<i>D. succinatiphilus</i>	CCTGTTTGCTCCCCACGCTTTTCGAGCCTCAACGTCAGT CATCGTCCAGCAAGCCGCCTTCGCCACTGGTGTTCCTC CTAATATCTACGCATTTACCGCTACACTAGGAATTCC ACTTTCCTCTCCGATACTCCAGCTTTCCAGTTTCCATCC CATCACGGGGTTAAGCCCCGCACTTTTAAGATGGACT TAGAAAGCCGCCTGCGCGCCTTTACGCCAATAATT CCGGACAACGCTTGCCACCTACGTA	21
#OTU_882	<i>D. invisus</i>	CCTGTTTGCTCCCCACGCTTTTCGAGCCTCAGCGTCAGT TAAAGCCCAGTAAGCCGCCTTCGCCACTGATGTTCTC CTAATATCTACGCATTTACCGCTACACTAGGAATTCC ACTTTCCTCTCCGATACTCCAGCTTTCCAGTTTCTTCC CATCACGGGGTTAAGCCCCGCACTTTTAAGAGGGACT TGGGAAGCCGCCTGCGCGCCTTTACGCCAATAATT CCGGACAACGCTTGCCACCTACGTA	22
# OTU_982	<i>D. pseudosintes</i>	CCCGTTCGCTCCCCTGGCTTTTCGCGCCTCAGCGTCAGT TTTCGTCCAGAAAGTCGCCTTCGCCACTGGTGTTCCTC CTAATATCTACGCATTTACCGCTACACTAGGAATTCC ACTTTCCTCTCCGATACTCCAGCTTTCCAGTTTCCATCC CCTCATGGGGTTGAGCCCCACGCTTTTAAGATGGACT TAAGAAACCGCCTGCGCGCCTTTACGCCAATAATTC CGGACAACGCTTGCCACCTACGTA	23
OTU_984	<i>D. pseudosintes</i>	CCTGTTTGCTCCCCACGCTTTTCGCGCCTCAGCGTCAGT TTTCGTCTAGAAAGTCGCCTTCGCCACCGGTGTTCCTC CTAATCTCTACGCATTTACCGCTACACTAGGAATTCC ACTTTCCTCTCCGATACTCCAGCTTTCCAGTTTCCATCC CCTCATGGGGTTGAGCCCCACGCTTTTAAGATGGACT TAAGAAACCGCCTGCGCGCCTTTACGCCAATAATTC CGGACAACGCTTGCCACCTACGTA	24

Table 5. Clinical characteristics of the SpA patients at baseline for the stool samples. For numerical variables, the first number is the mean with between parentheses the minimum and maximum values. NSAID index was calculated for 3 months preceding ileocolonoscopy. F: female, M: male, AS: Ankylosing Spondylitis, nr-axSpA: non-radiographic axial spondyloarthritis, PS: peripheral SpA, CRP: C-reactive protein, BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, ASDAS: Ankylosing Spondylitis Disease Activity Score, N: non-smoker, F: former smoker and C: current smoker. NSAIDs: non-steroidal anti-inflammatory drugs.

5

	Normal Histology	Acute inflammation	Chronic inflammation
	(N = 31)	(N = 9)	(N = 6)
Sex	17F, 14M	5F, 4M	2F, 4M
Age (years)	37 (23-56)	35 (24-48)	34 (22-61)
Diagnosis	11 AS, 18 nr-axSpA, 2 PS	1 AS, 6 nr-axSpA, 2 PS	2 AS, 1 nr-axSpA, 1 PS
CRP (mg/dL)	0.68 (0-3.48)	1.25 (0.1-6.9)	2 (0.5-7.6)
BASDAI	4.52 (0.6-8.1)	5.16 (2.5-7.8)	4.1 (2.4-6.1)
ASDAS	2.64 (1.1-4.4)	3.08 (1.2-3.8)	3 (1.7-5)
HLA-B27	21(+) 9(-) 1?	6(+) 3(-)	5(+) 1(-)
Smoking status	13N, 9F, 9C	5N, 3F, 1C	2N, 2F, 1C, 1?
NSAID index (%)	50 (0-92)	46 (0-100)	49 (0-92)

CLAIMS

1. A method to detect the presence or to assess the risk of development of an inflammatory arthritis disease in a patient, comprising the steps of:

- 5
- determining a gut microbiome profile for said patient, said gut microbiome profile comprising an indication of the presence and/or abundance of at least *Dialister* spp. and comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles, wherein said one or more gut microbiome reference profiles comprise at least one of a positive gut microbiome reference profile based on results from control subjects with said inflammatory arthritis disease and a negative gut microbiome reference profile based on results from control

10

 - subjects without said inflammatory arthritis disease,
 - if said gut microbiome profile for said patient statistically significantly matches said positive gut microbiome reference profile, then concluding that said patient has or is at risk of developing said inflammatory arthritis disease; and/or
 - if said gut microbiome profile for said patient statistically significantly matches said negative gut

15

 - microbiome reference profile, then concluding that said patient does not have or is not at risk of developing said inflammatory arthritis disease.

2. The method according to claim 1, to detect the presence of or to assess the risk of development of joint inflammation in a patient with an inflammatory arthritis disease, said method comprising the steps of:

- 20
- determining a gut microbiome profile for said patient, said gut microbiome profile comprising an indication of the presence and/or abundance of at least *Dialister* spp. and comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles, wherein said one or more gut microbiome reference profiles comprise at least one of a positive gut microbiome reference profile based on results from control subjects with joint inflammation and

25

 - a negative gut microbiome reference profile based on results from control subjects without joint inflammation,
 - if said gut microbiome profile for said patient statistically significantly matches said positive gut microbiome reference profile, then concluding that said patient has or is at risk of developing joint inflammation; and/or
 - if said gut microbiome profile for said patient statistically significantly matches said negative gut

30

 - microbiome reference profile, then concluding that said patient does not have or is not at risk of developing joint inflammation.

3. The method according to claim 1, to detect the presence of or to assess the risk of development of gut inflammation in a patient with an inflammatory arthritis disease, said method comprising the steps of:
- determining a gut microbiome profile for said patient, said gut microbiome profile comprising an indication of the presence and/or abundance of at least *Dialister* spp. and comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles, wherein said one or more gut microbiome reference profiles comprise at least one of a positive gut microbiome reference profile based on results from control subjects with gut inflammation and a negative gut microbiome reference profile based on results from control subjects without gut inflammation,
 - if said gut microbiome profile for said patient statistically significantly matches said positive gut microbiome reference profile, then concluding that said patient has or is at risk of developing gut inflammation; and/or
 - if said gut microbiome profile for said patient statistically significantly matches said negative gut microbiome reference profile, then concluding that said patient does not have or is not at risk of developing gut inflammation.
4. A method of monitoring the efficacy of a treatment for an inflammatory arthritis disease in a patient, said method comprising the steps of:
- determining a gut microbiome profile for said patient, said gut microbiome profile comprising an indication of the presence and/or abundance of at least *Dialister* spp. and comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles, wherein said one or more gut microbiome reference profiles comprise one or more of a positive gut microbiome reference profile based on results from control subjects with said inflammatory arthritis disease and a negative gut microbiome reference profile based on results from control subjects without said inflammatory arthritis disease; and
 - if said gut microbiome profile for said patient statistically significantly matches said positive gut microbiome reference profile, then concluding that said treatment is not efficacious; and/or
 - if said gut microbiome profile for said patient deviates statistically significantly from said negative gut microbiome reference profile, then concluding that said treatment is efficacious,
- wherein said analyzing and comparing steps are performed at one or more successive time points with samples collected from said patient at one or more successive time periods during said treatment.

5. The method according claim 4, to monitor the efficacy of a treatment for joint and/or gut inflammation in a patient with an inflammatory arthritis disease, said method comprising the steps of:

- determining a gut microbiome profile for said patient, said gut microbiome profile comprising an indication of the presence and/or abundance of at least *Dialister* spp. and comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles, wherein said one or more gut microbiome reference profiles comprise one or more of a positive gut microbiome reference profile based on results from control subjects with joint inflammation in case said patient has or is having a likelihood of developing joint inflammation or one or more of a positive gut microbiome reference profile based on results from control subjects with gut inflammation in case said patient has or is having a likelihood of developing gut inflammation and a negative gut microbiome reference profile based on results from control subjects without joint inflammation in case said patient has or is having a likelihood of developing joint inflammation or from control subject without gut inflammation in case said patient has or is having a likelihood of developing gut inflammation; and
- if said gut microbiome profile for said patient statistically significantly matches said positive gut microbiome reference profile, then concluding that said treatment is not efficacious; and/or
- if said gut microbiome profile for said patient deviates statistically significantly from said negative gut microbiome reference profile, then concluding that said treatment is efficacious,

wherein said analyzing and comparing steps are performed at one or more successive time points with samples collected from said patient at one or more successive time periods during said treatment.

6. A method of assessing the disease activity or a change in disease activity in a patient suffering from an inflammatory arthritis disease, said method comprising the steps of:

- determining a gut microbiome profile for said patient, wherein said gut microbiome profile comprises an indication of the presence and/or abundance of at least *Dialister* spp., and comparing said gut microbiome profile of said patient to one or more gut microbiome reference profiles each characteristic for a different stage of the disease, wherein said one or more gut microbiome reference profiles are based on results from control subjects that are characterized by different disease activities of said inflammatory arthritis disease; and
- if said gut microbiome profile for said patient statistically significantly matches said one or more gut microbiome reference profile each characteristic for a different stage of the disease, then a

disease activity score or a change in disease activity score is obtained for said inflammatory arthritis disease.

- 5 7. A method to detect the presence or to assess the risk of development of an inflammatory arthritis disease in a patient, comprising the steps of:
- determining the abundance of a *Dialister* spp. in a biological sample of said patient;
 - if said abundance for said patient is at least 10% higher than the abundance of said *Dialister* spp. in said biological sample of a control subject without said inflammatory arthritis disease, then concluding that said patient has or is at risk of developing said inflammatory arthritis disease.
- 10
8. The method according to claim 7, to detect the presence or to assess the risk of development of joint or gut inflammation in a patient with an inflammatory arthritis disease, said method comprising the steps of:
- determining the abundance of a *Dialister* spp. in a biological sample of said patient;
 - 15 - if said abundance for said patient is at least 10% higher than the abundance of said *Dialister* spp. in said biological sample of a control subject without joint or gut inflammation, then concluding that said patient has or is at risk of developing joint or gut inflammation.
9. A method of designing a treatment for an inflammatory arthritis disease in a patient, comprising the steps of
- 20 applying the method of claim 1 or claim 7 to said patient at one or more successive time points, whereby if said patient has or is at risk for developing said inflammatory arthritis disease, then selecting an appropriate treatment, and treating the patient according to said selected treatment.
10. A method of monitoring the efficacy of a treatment for an inflammatory arthritis disease in a patient, said method comprising the steps of:
- 25
- determining the abundance of a *Dialister* spp. in a biological sample of said patient at two or more successive time points with biological samples collected from said patient at two or more successive time periods during said treatment;
 - if the abundance of said *Dialister* spp. for said patient at a later time point of said two or more
- 30 successive time points is at least 10% lower than the abundance of said *Dialister* spp. at an earlier

time point of said two or more successive time points, then concluding that said treatment is efficacious.

11. The method according to claim 10, to monitor the efficacy of a treatment for joint or gut
5 inflammation in a patient with an inflammatory arthritis disease, wherein said method comprises the steps of:

- determining the abundance of a *Dialister* spp. in a biological sample of said patient at two or more successive time points with biological samples collected from said patient at two or more successive time periods during said treatment;
- 10 - if the abundance of said *Dialister* spp. for said patient at a later time point of said two or more successive time points is at least 10% lower than the abundance of said *Dialister* spp. at an earlier time point of said two or more successive time points, then concluding that said treatment is efficacious.

12. The method of any of claims 1-11, wherein said biological sample is selected from a mucosal biopsy
15 sample, a stool sample, a sample of the lumen content, an oral sample, a blood sample, a serum sample or a urine sample.

13. The method of any of claims 1-12, wherein said *Dialister* spp. is selected from the list consisting of
20 *Dialister invisus*, *Dialister propionifaciens*, *Dialister succinatiphilus*, *Dialister microaerophilus* and *Dialister pneumosintes*.

14. The method according to any of claims 1-13, wherein said inflammatory arthritis disease is
spondyloarthritis.

15. Use of a gut microbiome profile to detect the presence or to assess the risk of development of an
inflammatory arthritis disease, or to assess disease activity in a patient with an inflammatory arthritis
disease, wherein said gut microbiome profile comprises an indication of the presence and/or
abundance of at least *Dialister* spp.

16. Use of a gut microbiome profile to detect the presence or to assess the risk of development of joint
and/or gut inflammation in a patient with an inflammatory arthritis disease, wherein said gut

microbiome profile comprises an indication of the presence and/or abundance of at least *Dialister* spp.

17. The use according to any of claims 15-16, wherein said *Dialister* spp. is selected from the list
5 consisting of *Dialister invisus*, *Dialister propionifaciens*, *Dialister succinatiphilus*, *Dialister micraerophilus* and *Dialister pneumosintes*.
18. The use according to claims 15-17, wherein said inflammatory arthritis disease is spondyloarthritis.
- 10 19. A diagnostic/prognostic kit for carrying out the methods according to any one of claims 1 to 18.
20. The method of any of claims 4, 5, 10 or 11, wherein said method is carried out prior to commencement of said treatment, during said treatment and/or after cessation of said treatment.
- 15 21. The method of any of claims 1-6 or 9, wherein a statistically significant match has a P value of 0.05 or less.
22. The method of any of claims 1-6, 9 or 21, wherein said gut microbiome profile includes one or more of: bacterial taxa identified in said gut microbiota; bacterial metabolic products in said gut microbiota;
20 and proteins in said gut microbiota.
23. The method of any of claims 1-6, 9, 21 or 22, wherein said gut microbiome profile is based on an analysis of amplification products of DNA and/or RNA in said gut microbiota.
- 25 24. The method of any of claims 4, 5, 9, 10, 11, wherein said treatment includes a biological therapy, such as TNF-alpha blockers, anti-IL17A monoclonal antibodies.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12





Figure 13



INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2016/082355

A. CLASSIFICATION OF SUBJECT MATTER
INV. C12Q1/68
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2015/170979 A1 (IS DIAGNOSTICS LTD [NL]) 12 November 2015 (2015-11-12)	2,4, 7-15, 19-24
Y	p. 3, and 4, p. 7 l. 10-30, -----	1,3,5
A	US 2015/225784 A1 (ZEICHNER STEVEN L [US] ET AL) 13 August 2015 (2015-08-13) [0007], and [0010] -----	1-24
A	WO 2015/013214 A2 (WHOLE BIOME INC [US]) 29 January 2015 (2015-01-29) [0010], [0011], [0016], [0017], [0021], [0022] ----- -/--	1-24

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search
3 March 2017

Date of mailing of the international search report
16/03/2017

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer
Lapopin, Laurence

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2016/082355

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	TANEJA VEENA: "Arthritis susceptibility and the gut microbiome", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 588, no. 22, 27 May 2014 (2014-05-27) , pages 4244-4249, XP029083057, ISSN: 0014-5793, DOI: 10.1016/J.FEBSLET.2014.05.034 Abstract, Fig. 2 and the list of bacteria p. 4245 and 4247 -----	1-24
Y	TIINA DRELL ET AL: "Differences in Gut Microbiota Between Atopic and Healthy Children", CURRENT MICROBIOLOGY, vol. 71, no. 2, 14 April 2015 (2015-04-14) , pages 177-183, XP055327058, Boston ISSN: 0343-8651, DOI: 10.1007/s00284-015-0815-9 abstract -----	1
Y	CN 104 546 939 A (BGI SHENZHEN CO LTD; BGI SHENZHEN) 29 April 2015 (2015-04-29) p. 2, 4th para. -----	1
Y	CLARA ABRAHAM ET AL: "Interactions Between the Host Innate Immune System and Microbes in Inflammatory Bowel Disease", GASTROENTEROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 140, no. 6, 3 February 2011 (2011-02-03), pages 1729-1737, XP028480606, ISSN: 0016-5085, DOI: 10.1053/J.GASTRO.2011.02.012 [retrieved on 2011-02-16] abstract -----	3,5
X	C. CASÉN ET AL: "Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD", ALIMENTARY PHARMACOLOGY & THERAPEUTICS., vol. 42, no. 1, 14 May 2015 (2015-05-14), pages 71-83, XP055351398, GB ISSN: 0269-2813, DOI: 10.1111/apt.13236 abstract -----	16-18

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2016/082355

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2015170979 A1	12-11-2015	CA 2948134 A1 EP 3140424 A1 WO 2015170979 A1	12-11-2015 15-03-2017 12-11-2015

US 2015225784 A1	13-08-2015	US 2015225784 A1 WO 2015123205 A1	13-08-2015 20-08-2015

WO 2015013214 A2	29-01-2015	CN 105407728 A GB 2535034 A JP 2016525355 A US 2015259728 A1 WO 2015013214 A2	16-03-2016 10-08-2016 25-08-2016 17-09-2015 29-01-2015

CN 104546939 A	29-04-2015	CN 104546939 A HK 1209357 A1	29-04-2015 01-04-2016
